- Accueil
- Le département
- Notre équipe
- Pr Solange Peters
Pr Solange Peters
MD, PhD
Professeure ordinaire UNIL
Médecin cheffe
Cheffe du Service d'oncologie médicale
Responsable de la Consultation spécialisée des tumeurs thoraciques
Service d'oncologie médicale
Département d'oncologie UNIL CHUV
Médecin responsable du Centre des tumeurs thoraciques
Contacter par mail
+41 21 314 44 62
Spécialisations
- Tumeurs thoraciques, incluant:
- Cancer bronchique non a petites cellules
- Cancer bronchiques a petites cellules
- Carcinoïdes bronchiques
- Tumeurs thymiques
- Mesotheliomes
- Tumeurs pleurales
- Métastases intrathoraciques
Domaines d'intérêt académique et/ou clinique
Tumeurs thoraciques, cancers pulmonaires et tumeurs pleurales.
Activités de recherche
Recherche fondamentale qui se focalise principalement sur les nouveaux biomarqueurs et leur validation au sein des procédures, études précliniques et cliniques, et enfin recommandations pour la prise en charge des patient-e-s au niveau européen.
Pr. Peters est également active dans les approches innovatives en termes de traitements multimodaux (radiothérapie, chimiothérapie et chirurgie) et gère l’organisation et la coordination d’essais cliniques, ainsi que les bases de données de l’European Thoracic Oncology Platform (ETOP). Cette large plateforme permet à ce jour d'étudier de multiples approches nouvelles dans le traitement des tumeurs thoraciques en Europe, mais aussi aux Etats-Unis et en Asie.
Études cliniques sélectionnées en cours
- Preoperative chemotherapy and radiotherapy concomitant to Cetuximab in non-small cell lung cancer (NSCLC) patients with IIIB disease. A multicenter phase II trial. SAKK 16/08
- A randomized phase III trial evaluating the addition of Denosumab to standard first-line anticancer treatment in advanced NSCLC. Survival improvement in Lung cancer induced by Denosumab therapy ETOP/EORTC SPLENDOUR
- A randomized phase II trial of consolidation ipilimumab vs observation in stage I-III ("limited disease") small cell lung cancer after chemoradiotherapy ETOP STIMULI
Publications scientifiques sélectionnées
Immunotherapy for advanced-stage squamous cell lung cancer: the state of the art and outstanding questions.
Wang Y, Safi M, Hirsch FR, Lu S, Peters S, Govindan R, Rosell R, Park K, Zhang JJ
Nat Rev Clin Oncol. 2025 Mar;22(3):200-214
Antibody-drug conjugates in NSCLC with actionable genomic alterations: Optimizing smart delivery of chemotherapy to the target.
Mountzios G, Saw SPL, Hendriks L, Menis J, Cascone T, Arrieta O, Naidoo J, Koutoukoglou P, Cani M, Lefevre A, Addeo A, Peters S, Remon J
Cancer Treat Rev. 2025 Feb 16;134:102902
Proceedings of the 1st biannual bridging the gaps in lung cancer conference.
Florez N, Patel SP, Wakelee H, Bazhenova L, Massarelli E, Salgia R, Stiles B, Peters S, Malhotra J, Gadgeel SM, Nieva JJ, Afkhami M, Hirsch FR, Gubens M, Cascone T, Levy B, Sabari J, Husain H, Ma PC, Backhus LM, Iyengar P, Lee P, Miller R, Sands J, Kim E
Oncologist. 2025 Feb 6;30(2)
Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry.
Cortellini A, Brunetti L, Di Fazio GR, Garbo E, Pinato DJ, Naidoo J, Katz A, Loza M, Neal JW, Genova C, Gettinger S, Kim SY, Jayakrishnan R, El Zarif T, Russano M, Pecci F, Di Federico A, Awad M, Alessi JV, Montrone M, Owen DH, Signorelli D, Fidler MJ, Li M, Camerini A, De Giglio A, Young L, Vincenzi B, Metro G, Passiglia F, Yendamuri S, Guida A, Ghidini M, Awosika NO, Napolitano A, Fulgenzi CAM, Grisanti S, Grossi F, D'Incecco A, Josephides E, Van Hemelrijck M, Russo A, Gelibter A, Spinelli G, Verrico M, Tomasik B, Giusti R, Newsom-Davis T, Bria E, Sebastian M, Rost M, Forster M, Mukherjee U, Landi L, Mazzoni F, Aujayeb A, Dupont M, Curioni-Fontecedro A, Chiari R, Pantano F, Morabito A, Leonetti A, Friedlaender A, Addeo A, Zoratto F, De Tursi M, Cantini L, Roca E, Mountzios G, Della Gravara L, Kalvapudi S, Inno A, Bironzo P, Di Marco Barros R, O'Reilly D, Bell J, Karapanagiotou E, Monnet I, Baena J, Macerelli M, Majem M, Agustoni F, Cortinovis DL, Tonini G, Minuti G, Bennati C, Mezquita L, Gorría T, Servetto A, Beninato T, Lo Russo G, Rogado J, Moliner L, Biello F, Aboubakar Nana F, Dingemans AM, Aerts JGJV, Ferrara R, Torri V, Hejleh TA, Takada K, Naqash AR, Garassino M, Peters S, Wakelee H, Nassar AH, Ricciuti B
J Immunother Cancer. 2025 Feb 4;13(2)
Hyperthermic Intrathoracic Chemotherapy Modulates the Immune Microenvironment of Pleural Mesothelioma and Improves the Impact of Dual Immune Checkpoint Inhibition.
Hao Y, Gkasti A, Managh AJ, Dagher J, Sifis A, Tiron L, Chriqui LE, Marie DN, De Souza Silva O, Christodoulou M, Peters S, Joyce JA, Krueger T, Gonzalez M, Abdelnour-Berchtold E, Sempoux C, Clerc D, Teixeira-Farinha H, Hübner M, Meylan E, Dyson PJ, Cavin S, Perentes JY
Cancer Immunol Res. 2025 Feb 3;13(2):185-199
Prevalence and Clinical Association of CD276 (B7-H3) Expression in Pleural Mesothelioma: Results From the European Thoracic Platform Mesoscape Project.
Haberecker M, Rüschoff JH, Andriakopoulou C, Gray SG, Nackaerts K, De Perrot M, Brcic L, Nadal E, Tsimpoukis S, Ampollini L, Aerts JG, Kirschner MB, Monkhorst K, Weynand B, Bavaghar-Zaeimi F, Samarzija M, Llatjos R, Finn SP, Silini E, Von Der Thüsen J, Vagenknecht P, Tsourti Z, Kerr KM, Kammler R, Peters S, Baas P, Opitz I, Stahel RA, Curioni-Fontecedro A, ETOP Mesoscape Consortium, TransSCOT Consortium
JCO Precis Oncol. 2025 Feb;9:e2400675
Landscape of subsequent therapies in perioperative immunotherapy trials across multiple cancer types.
Semaan K, Nawfal R, Nally E, Janjigian YY, Robert C, Peters S, Powles T, Choueiri TK
Lancet Oncol. 2025 Feb;26(2):161-164
First-Line Mobocertinib Versus Platinum-Based Chemotherapy in Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer in the Phase III EXCLAIM-2 Trial.
Jänne PA, Wang BC, Cho BC, Zhao J, Li J, Hochmair M, Peters S, Besse B, Pavlakis N, Neal JW, Kato T, Wu YL, Nguyen D, Lin J, Lin J, Vranceanu F, Szumski A, Lin HM, Fram RJ, Mok TSK
J Clin Oncol. 2025 Jan 29:JCO2401269
Adjuvant Immunotherapy Should Be Used in Patients With Non-Small Cell Carcinoma With a Pathologic Complete Response to Neoadjuvant Immunotherapy.
Uprety D, Roden AC, Peters S
J Thorac Oncol. 2025 Jan;20(1):34-38
Immunotherapy or targeted therapy with or without stereotactic radiosurgery for patients with brain metastases from melanoma or non-small cell lung cancer - The ETOP 19-21 USZ-STRIKE study.
Weller M, Le Rhun E, Tsamtsouri L, Dummer R, Guckenberger M, Ribi K, di Giacomo AM, Minuti G, Collazo-Lorduy A, Brandsma D, O'Brien M, Ermis E, Fischer N, Ascierto P, Mandala M, Minniti G, Iranzo P, Roschitzki-Voser H, Ruepp B, Grolimund E, Dafni U, Peters S, Stahel R, ETOP 19-21 USZ-STRIKE collaborators
Lung Cancer. 2025 Jan;199:108069
Lurbinectedin is an effective alternative to platinum rechallenge and may restore platinum sensitivity in patients with sensitive relapsed small cell lung cancer.
Dómine Gómez M, Subbiah V, Peters S, Sala MA, Trigo J, Paz-Ares L, Nieto Archilla A, Gomez Garcia J, Alvarez García C, López-Vilariño de Ramos JA, Kahatt Lopez C, Fernandez CM
Expert Rev Anticancer Ther. 2025 Jan;25(1):27-40
Long-Term Survival Outcomes With First-Line Nivolumab Plus Ipilimumab-Based Treatment in Patients With Metastatic NSCLC and Tumor Programmed Death-Ligand 1 Lower Than 1%: A Pooled Analysis.
Peters S, Paz-Ares LG, Reck M, Carbone DP, Brahmer JR, Borghaei H, Lu S, O'Byrne KJ, John T, Ciuleanu TE, Schenker M, Bernabe Caro R, Nishio M, Cobo M, Lee JS, Zurawski B, Pluzanski A, Aoyama T, Tschaika M, Devas V, Grootendorst DJ, Ramalingam SS
J Thorac Oncol. 2025 Jan;20(1):94-108
Durvalumab With or Without Tremelimumab in Combination With Chemotherapy in First-Line Metastatic NSCLC: Five-Year Overall Survival Outcomes From the Phase 3 POSEIDON Trial.
Peters S, Cho BC, Luft AV, Alatorre-Alexander J, Geater SL, Laktionov K, Trukhin D, Kim SW, Ursol GM, Hussein M, Lim FL, Yang CT, Araujo LH, Saito H, Reinmuth N, Lowery C, Mann H, Stewart R, Jiang H, Garon EB, Mok T, Johnson ML
J Thorac Oncol. 2025 Jan;20(1):76-93
Identifying the drivers of overall rating of cancer care: Insights from the second wave of the Swiss Cancer Patient Experiences study.
Jolidon V, Eicher M, Peytremann-Bridevaux I, Aebi S, Anchisi S, Bettini A, Chalandon Y, Dietrich PY, Duchosal MA, Dürr D, Peters S, von Moos R, Wicki A, Arditi C
Cancer. 2024 Dec 15;130(24):4334-4346
Calls to action on lung cancer management and research.
Meyer ML, Hirsch FR, Bunn PA, Ujhazy P, Fredrickson D, Berg CD, Carbone DP, Halmos B, Singh H, Borghaei H, Ferris A, Langer C, Dacic S, Mok TS, Peters S, Johnson BE
Oncologist. 2024 Dec 6;29(12):e1634-e1645
ctDNA Dynamics and Mechanisms of Acquired Resistance in Patients Treated with Osimertinib with or without Bevacizumab from the Randomized Phase II ETOP-BOOSTER Trial.
Soo RA, Dafni U, Han JY, Cho BC, Nadal E, Yeo CM, Carcereny E, de Castro J, Sala MA, Coate L, Provencio M, Britschgi C, Vagenknecht P, Dimopoulou G, Kammler R, Finn SP, Peters S, Stahel RA, ETOP 10-16 BOOSTER Collaborators
Clin Cancer Res. 2024 Nov 15;30(22):5180-5191
Association of Antibody-Drug Conjugate (ADC) Target Expression and Interstitial Lung Disease (ILD) in Non-Small-Cell Lung Cancer (NSCLC): Association or Causation or Neither?
Desai A, Subbiah V, Roy-Chowdhuri S, Sheshadri A, Deshmukh S, Peters S
Cancers (Basel). 2024 Nov 7;16(22)
CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors.
Skoulidis F, Araujo HA, Do MT, Qian Y, Sun X, Cobo AG, Le JT, Montesion M, Palmer R, Jahchan N, Juan JM, Min C, Yu Y, Pan X, Arbour KC, Vokes N, Schmidt ST, Molkentine D, Owen DH, Memmott R, Patil PD, Marmarelis ME, Awad MM, Murray JC, Hellyer JA, Gainor JF, Dimou A, Bestvina CM, Shu CA, Riess JW, Blakely CM, Pecot CV, Mezquita L, Tabbó F, Scheffler M, Digumarthy S, Mooradian MJ, Sacher AG, Lau SCM, Saltos AN, Rotow J, Johnson RP, Liu C, Stewart T, Goldberg SB, Killam J, Walther Z, Schalper K, Davies KD, Woodcock MG, Anagnostou V, Marrone KA, Forde PM, Ricciuti B, Venkatraman D, Van Allen EM, Cummings AL, Goldman JW, Shaish H, Kier M, Katz S, Aggarwal C, Ni Y, Azok JT, Segal J, Ritterhouse L, Neal JW, Lacroix L, Elamin YY, Negrao MV, Le X, Lam VK, Lewis WE, Kemp HN, Carter B, Roth JA, Swisher S, Lee R, Zhou T, Poteete A, Kong Y, Takehara T, Paula AG, Parra Cuentas ER, Behrens C, Wistuba II, Zhang J, Blumenschein GR, Gay C, Byers LA, Gibbons DL, Tsao A, Lee JJ, Bivona TG, Camidge DR, Gray JE, Leighl NB, Levy B, Brahmer JR, Garassino MC, Gandara DR, Garon EB, Rizvi NA, Scagliotti GV, Wolf J, Planchard D, Besse B, Herbst RS, Wakelee HA, Pennell NA, Shaw AT, Jänne PA, Carbone DP, Hellmann MD, Rudin CM, Albacker L, Mann H, Zhu Z, Lai Z, Stewart R, Peters S, Johnson ML, Wong KK, Huang A, Winslow MM, Rosen MJ, Winters IP, Papadimitrakopoulou VA, Cascone T, Jewsbury P, Heymach JV
Nature. 2024 Nov;635(8038):462-471
Multicenter Study on Tumor Budding in Lung Squamous Cell Carcinoma: Comparison Between Biopsy and Resection With Interobserver Variability Assessment.
Maillard M, Neppl C, Zens P, Anex J, Peters S, Krueger T, Berezowska S
Mod Pathol. 2024 Oct;37(10):100571
Tumour mutational burden: clinical utility, challenges and emerging improvements.
Budczies J, Kazdal D, Menzel M, Beck S, Kluck K, Altbürger C, Schwab C, Allgäuer M, Ahadova A, Kloor M, Schirmacher P, Peters S, Krämer A, Christopoulos P, Stenzinger A
Nat Rev Clin Oncol. 2024 Oct;21(10):725-742
New promises and challenges in the treatment of advanced non-small-cell lung cancer.
Meyer ML, Fitzgerald BG, Paz-Ares L, Cappuzzo F, Jänne PA, Peters S, Hirsch FR
Lancet. 2024 Aug 24;404(10454):803-822
ROS1 fusions in resected stage I-III adenocarcinoma: Results from the European Thoracic Oncology Platform Lungscape project.
Speel EM, Dafni U, Thunnissen E, Hendrik Rüschoff J, O'Brien C, Kowalski J, Kerr KM, Bubendorf L, Sansano I, Joseph L, Kriegsmann M, Navarro A, Monkhorst K, Bille Madsen L, Hernandez Losa J, Biernat W, Stenzinger A, Rüland A, Hillen LM, Marti N, Molina-Vila MA, Dellaporta T, Kammler R, Peters S, Stahel RA, Finn SP, Radonic T, Lungscape Consortium (see Appendix)
Lung Cancer. 2024 Aug;194:107860
KRAS and TP53 co-mutation predicts benefit of immune checkpoint blockade in lung adenocarcinoma.
Budczies J, Romanovsky E, Kirchner M, Neumann O, Blasi M, Schnorbach J, Shah R, Bozorgmehr F, Savai R, Stiewe T, Peters S, Schirmacher P, Thomas M, Kazdal D, Christopoulos P, Stenzinger A
Br J Cancer. 2024 Aug;131(3):524-533
Safety of pembrolizumab as adjuvant therapy in a pooled analysis of phase 3 clinical trials of melanoma, non-small cell lung cancer, and renal cell carcinoma.
Luke JJ, Long GV, Robert C, Carlino MS, Choueiri TK, Haas NB, O'Brien M, Paz-Ares L, Peters S, Powles T, Leiby MA, Lin J, Zhao Y, Krepler C, Perini RF, Catherine Pietanza M, Samkari A, Gruber T, Ibrahim N, Eggermont AMM
Eur J Cancer. 2024 Aug;207:114146
Entrectinib in ROS1-positive advanced non-small cell lung cancer: the phase 2/3 BFAST trial.
Peters S, Gadgeel SM, Mok T, Nadal E, Kilickap S, Swalduz A, Cadranel J, Sugawara S, Chiu CH, Yu CJ, Moskovitz M, Tanaka T, Nersesian R, Shagan SM, Maclennan M, Mathisen M, Bhagawati-Prasad V, Diarra C, Assaf ZJ, Archer V, Dziadziuszko R
Nat Med. 2024 Jul;30(7):1923-1932
Brief Report: Impact of Anti-Cancer Treatments on Outcomes of COVID-19 in Patients With Thoracic Cancers: A CCC19 Registry Analysis.
Kulkarni AA, Hennessy C, Wilson G, Ramesh V, Hwang C, Awosika J, Bakouny Z, Khan H, Vilar-Compte D, McKay R, Jani C, Weissmann L, Griffiths E, Batist G, Bouganim N, Mavromatis B, Bashir B, Nguyen RH, Riess JW, Puc M, Kasi A, Berg S, Castillo DR, Hayes-Lattin B, Hosmer W, Flora D, Mishra S, French B, Warner JL, Lopes G, Peters S, Florez N
Clin Lung Cancer. 2024 Jul;25(5):e229-e237.e7
A pharmacist-led interprofessional medication adherence program improved adherence to oral anticancer therapies: The OpTAT randomized controlled trial.
Bandiera C, Cardoso E, Locatelli I, Zaman K, Diciolla A, Digklia A, Stravodimou A, Cristina V, Aedo-Lopez V, Dolcan A, Sarivalasis A, Bouchaab H, Pasquier J, Dotta-Celio J, Peters S, Wagner D, Csajka C, Schneider MP
PLoS One. 2024;19(6):e0304573
NTRK gene fusion testing and management in lung cancer.
Repetto M, Chiara Garassino M, Loong HH, Lopez-Rios F, Mok T, Peters S, Planchard D, Popat S, Rudzinski ER, Drilon A, Zhou C
Cancer Treat Rev. 2024 Jun;127:102733
Beyond Chemoimmunotherapy in Advanced Non-Small Cell Lung Cancer: New Frontiers, New Challenges.
Mountzios G, Naidoo J, Wang C, Creelan BC, Trotier DC, Campbell TC, Peters S
Am Soc Clin Oncol Educ Book. 2024 Jun;44(3):e432526
L’immunothérapie en oncologie : entre espoirs, défis et équité.
Peters S, Addeo A, Herrera FG
Rev Med Suisse. 2024 May 15;20(874):951-952
A Brief Report of Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: Outcomes by Tumor PD-L1 Expression in the Phase 3 POSEIDON Study.
Garon EB, Cho BC, Luft A, Alatorre-Alexander J, Geater SL, Trukhin D, Kim SW, Ursol G, Hussein M, Lim FL, Yang CT, Araujo LH, Saito H, Reinmuth N, Kohlmann M, Lowery C, Mann H, Peters S, Mok TS, Johnson ML
Clin Lung Cancer. 2024 May;25(3):266-273.e5
Primary prophylaxis with mTOR inhibitor enhances T cell effector function and prevents heart transplant rejection during talimogene laherparepvec therapy of squamous cell carcinoma.
Joo V, Abdelhamid K, Noto A, Latifyan S, Martina F, Daoudlarian D, De Micheli R, Pruijm M, Peters S, Hullin R, Gaide O, Pantaleo G, Obeid M
Nat Commun. 2024 Apr 30;15(1):3664
Long-Term Results of Stereotactic Radiotherapy in Patients with at Least 10 Brain Metastases at Diagnosis.
Kinj R, Hottinger AF, Böhlen TT, Ozsahin M, Vallet V, Dunet V, Bouchaab H, Peters S, Tuleasca C, Bourhis J, Schiappacasse L
Cancers (Basel). 2024 Apr 29;16(9)
Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors.
Peters S, Angevin E, Alonso-Gordoa T, Rohrberg K, Melero I, Mellado B, Perez-Gracia JL, Tabernero J, Adessi C, Boetsch C, Watson C, Dal Porto J, Dejardin D, Del Nagro C, Nicolini V, Evers S, Klein C, Leutgeb B, Pisa P, Rossmann E, Saro J, Umana P, Charo J, Teichgräber V, Steeghs N
Clin Cancer Res. 2024 Apr 15;30(8):1630-1641
Adjuvant Alectinib in ALK-Rearranged NSCLC - Here and Now.
Passaro A, Peters S
N Engl J Med. 2024 Apr 11;390(14):1325-1327
Cancer biomarkers: Emerging trends and clinical implications for personalized treatment.
Passaro A, Al Bakir M, Hamilton EG, Diehn M, André F, Roy-Chowdhuri S, Mountzios G, Wistuba II, Swanton C, Peters S
Cell. 2024 Mar 28;187(7):1617-1635
Lung Cancer in Switzerland.
Werner RS, Curioni-Fontecedro A, Mauti LA, Addeo A, Peters S, Frauenfelder T, Puhan MA, Haberecker M, Bubendorf L, Finazzi T, Guckenberger M, Cafarotti S, Geiser T, Opitz I, SAKK
J Thorac Oncol. 2024 Mar;19(3):385-394
Lurbinectedin in patients with small cell lung cancer with chemotherapy-free interval ≥30 days and without central nervous metastases.
Peters S, Trigo J, Besse B, Moreno V, Navarro A, Eugenia Olmedo M, Paz-Ares L, Grohé C, Antonio Lopez-Vilariño J, Fernández C, Kahatt C, Alfaro V, Nieto A, Zeaiter A, Subbiah V
Lung Cancer. 2024 Feb;188:107448
First-Line Dual Immunotherapy, a Treatment Option in First-Line Metastatic Non-Small-Cell Lung Cancer: Are We Ready to Use It?
Uprety D, Remon J, Peters S
J Clin Oncol. 2024 Feb 1;42(4):378-382
[Oncology: what's new in 2023].
Jankovic J, Abdelhamid K, Berthold D, Desbaillets N, Bouchaab H, Dei Tos G, Demicheli R, Diciolla A, Digklia A, Ferraro DA, Florez L, Galli-Vareia I, Hottinger A, Latifyan S, Liapi A, Mederos N, Giacomuzzi Moore B, Sakr R, Stamatiou A, Wagner AD, Peters S, Sarivalasis A, Vanniere F, Zaman K, Stravodimou A
Rev Med Suisse. 2024 Jan 17;20(856-7):80-87
Phase I clinical trial testing the dose escalation and expansion of Pressurized IntraThoracic Hyperthermic Aerosol Cisplatin administration (PITHAC) for the management of pleural carcinosis.
Chriqui LE, Abdelnour-Berchtold E, Zanfrini E, Devesa-Perez S, Gonzalez M, Krueger T, Ellefsen K, Destaillats A, Bonnet D, Hübner M, Bouchaab H, Bassani-Sternberg M, Peters S, Cavin S, Perentes JY
Cancer Treat Res Commun. 2024;42:100858
Face to face among different chemo-immunotherapy combinations in the first line treatment of patients with advanced non-small cell lung cancer: Results of an international expert panel meeting by the italian association of thoracic oncology (AIOT).
Gridelli C, Peters S, Mok T, Garassino M, Paz-Ares L, Attili I, de Marinis F
Lung Cancer. 2024 Jan;187:107441
The KEYVIBE program: vibostolimab and pembrolizumab for the treatment of advanced malignancies.
Shapira-Frommer R, Niu J, Perets R, Peters S, Shouse G, Lugowska I, Garassino MC, Sands J, Keenan T, Zhao B, Healy J, Ahn MJ
Future Oncol. 2024;20(27):1983-1991
Disparities in outcomes between Black and White patients in North America with thoracic malignancies and COVID-19 infection (TERAVOLT).
Burns L, Hsu CY, Whisenant JG, Marmarelis ME, Presley CJ, Reckamp KL, Khan H, Jo Fidler M, Bestvina CM, Brahmer J, Puri S, Patel JD, Halmos B, Hirsch FR, Liu SV, Costa DB, Goldberg SB, Feldman LE, Mamdani H, Puc M, Mansfield AS, Islam N, Scilla KA, Garassino MC, Horn L, Peters S, Wakelee HA, Charlot M, Tapan U
Lung Cancer. 2023 Dec;186:107423
Patient-reported outcomes with durvalumab, with or without tremelimumab, plus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer (POSEIDON).
Garon EB, Cho BC, Luft A, Alatorre-Alexander J, Geater SL, Kim SW, Ursol G, Hussein M, Lim FL, Yang CT, Araujo LH, Saito H, Reinmuth N, Medic N, Mann H, Shi X, Peters S, Mok T, Johnson M
Lung Cancer. 2023 Dec;186:107422
[Lung cancer screening : towards the implementation of a pilot project in Switzerland].
Bongard C, Rey Cobo J, Messe R, Noirez L, Lovis A, Krueger T, Peters S, Pozzessere C, Selby K, von Garnier C
Rev Med Suisse. 2023 Nov 15;19(850):2165-2171
Dostarlimab or pembrolizumab plus chemotherapy in previously untreated metastatic non-squamous non-small cell lung cancer: the randomized PERLA phase II trial.
Lim SM, Peters S, Ortega Granados AL, Pinto GDJ, Fuentes CS, Lo Russo G, Schenker M, Ahn JS, Reck M, Szijgyarto Z, Huseinovic N, Zografos E, Buss E, Stjepanovic N, O'Donnell S, de Marinis F
Nat Commun. 2023 Nov 11;14(1):7301
Immune-checkpoint inhibition for resectable non-small-cell lung cancer - opportunities and challenges.
Mountzios G, Remon J, Hendriks LEL, García-Campelo R, Rolfo C, Van Schil P, Forde PM, Besse B, Subbiah V, Reck M, Soria JC, Peters S
Nat Rev Clin Oncol. 2023 Oct;20(10):664-677
PD-1-expressing macrophages and CD8 T cells are independent predictors of clinical benefit from PD-1 inhibition in advanced mesothelioma.
Homicsko K, Zygoura P, Norkin M, Tissot S, Shakarishvili N, Popat S, Curioni-Fontecedro A, O'Brien M, Pope A, Shah R, Fisher P, Spicer J, Roy A, Gilligan D, Rusakiewicz S, Fortis E, Marti N, Kammler R, Finn SP, Coukos G, Dafni U, Peters S, Stahel RA
J Immunother Cancer. 2023 Oct;11(10)
Patient-Reported Health-Related Quality of Life in KEYNOTE-604: Pembrolizumab or Placebo Added to Etoposide and Platinum as First-Line Therapy for Extensive-Stage SCLC.
Kim HR, Awad MM, Navarro A, Gottfried M, Peters S, Csőszi T, Cheema PK, Rodriguez-Abreu D, Wollner M, Yang JC, Mazieres J, Orlandi FJ, Luft A, Gümüş M, Kato T, Kalemkerian GP, Luo Y, Santorelli ML, Pietanza MC, Rudin CM
JTO Clin Res Rep. 2023 Nov;4(11):100572
European Epidemiology of Pleural Mesothelioma-Real-Life Data From a Joint Analysis of the Mesoscape Database of the European Thoracic Oncology Platform and the European Society of Thoracic Surgery Mesothelioma Database.
Opitz I, Bille A, Dafni U, Nackaerts K, Ampollini L, de Perrot M, Brcic L, Nadal E, Syrigos K, Gray SG, Aerts J, Curioni-Fontecedro A, Rüschoff JH, Monkhorst K, Weynand B, Silini EM, Bavaghar-Zaeimi F, Jakopovic M, Llatjos R, Tsimpoukis S, Finn SP, von de
J Thorac Oncol. 2023 Sep;18(9):1233-1247
First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a phase 3, global, multicentre, open-label, randomised controlled study.
Lee SM, Schulz C, Prabhash K, Kowalski D, Szczesna A, Han B, Rittmeyer A, Talbot T, Vicente D, Califano R, Cortinovis D, Le AT, Huang D, Liu G, Cappuzzo F, Reyes Contreras J, Reck M, Palmero R, Mak MP, Hu Y, Morris S, Höglander E, Connors M, Biggane AM, V
Lancet. 2023 Aug 5;402(10400):451-463
Adjuvant Treatments for Surgically Resected Non-Small Cell Lung Cancer Harboring EGFR Mutations: A Review.
Passaro A, Mok TSK, Attili I, Wu YL, Tsuboi M, de Marinis F, Peters S
JAMA Oncol. 2023 Aug 1;9(8):1124-1131
Systemic and Intracranial Outcomes With First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC and Baseline Brain Metastases From CheckMate 227 Part 1.
Reck M, Ciuleanu TE, Lee JS, Schenker M, Zurawski B, Kim SW, Mahave M, Alexandru A, Peters S, Pluzanski A, Caro RB, Linardou H, Burgers JA, Nishio M, Martinez-Marti A, Azuma K, Axelrod R, Paz-Ares LG, Ramalingam SS, Borghaei H, O'Byrne KJ, Li L, Bushong J
J Thorac Oncol. 2023 Aug;18(8):1055-1069
Antibody-Drug Conjugates in Lung Cancer: Recent Advances and Implementing Strategies.
Passaro A, Jänne PA, Peters S
J Clin Oncol. 2023 Jul 20;41(21):3747-3761
The Utility of ctDNA in Lung Cancer Clinical Research and Practice: A Systematic Review and Meta-Analysis of Clinical Studies.
Sun X, Abrahamson P, Ballew N, Kalilani L, Phiri K, Bell KF, Slowley A, Zajac M, Hofstatter E, Stojadinovic A, Silvestro A, Wang Z, Aziez A, Peters S
Cancer Invest. 2023 Jul;41(6):571-592
Cytokine storm complicated by cardiogenic shock induced by anti-HER2 therapies.
Godinho R, Noto A, Fenwick C, Stravodimou A, Hugelshofer S, Peters S, Hullin R, Obeid M
J Immunother Cancer. 2023 Jun;11(6)
Spatial profiling of the microenvironment reveals low intratumoral heterogeneity and STK11-associated immune evasion in therapy-naïve lung adenocarcinomas.
Goldschmid H, Kluck K, Ball M, Kirchner M, Allgäuer M, Winter H, Herth F, Heußel CP, Pullamsetti SS, Savai R, Yong TTK, Schirmacher P, Peters S, Thomas M, Christopoulos P, Budczies J, Stenzinger A, Kazdal D
Lung Cancer. 2023 Jun;180:107212
Carrières en oncologie et leadership féminin : les progrès sont-ils au point mort ?
Peters S, Addeo A, Aapro M
Rev Med Suisse. 2023 May 17;19(827):929-930
Population pharmacokinetic modelling of tremelimumab in patients with advanced solid tumours and the impact of disease status on time-varying clearance.
Hwang M, Chia YL, Zheng Y, Chen CC, He J, Song X, Zhou D, Goldberg SB, Siu LL, Planchard D, Peters S, Mann H, Krug L, Even C
Br J Clin Pharmacol. 2023 May;89(5):1601-1616
Immunotherapy-based combinations in metastatic NSCLC.
Desai A, Peters S
Cancer Treat Rev. 2023 May;116:102545
Adjuvant therapies in stages I-III epidermal growth factor receptor-mutated lung cancer: current and future perspectives.
Kris MG, Mitsudomi T, Peters S
Transl Lung Cancer Res. 2023 Apr 28;12(4):824-836
A neutrophil response linked to tumor control in immunotherapy.
Gungabeesoon J, Gort-Freitas NA, Kiss M, Bolli E, Messemaker M, Siwicki M, Hicham M, Bill R, Koch P, Cianciaruso C, Duval F, Pfirschke C, Mazzola M, Peters S, Homicsko K, Garris C, Weissleder R, Klein AM, Pittet MJ
Cell. 2023 Mar 30;186(7):1448-1464.e20
Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRAS(G12C) mutation: a randomised, open-label, phase 3 trial.
de Langen AJ, Johnson ML, Mazieres J, Dingemans AC, Mountzios G, Pless M, Wolf J, Schuler M, Lena H, Skoulidis F, Yoneshima Y, Kim SW, Linardou H, Novello S, van der Wekken AJ, Chen Y, Peters S, Felip E, Solomon BJ, Ramalingam SS, Dooms C, Lindsay CR, Fer
Lancet. 2023 Mar 4;401(10378):733-746
Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: The Phase III POSEIDON Study.
Johnson ML, Cho BC, Luft A, Alatorre-Alexander J, Geater SL, Laktionov K, Kim SW, Ursol G, Hussein M, Lim FL, Yang CT, Araujo LH, Saito H, Reinmuth N, Shi X, Poole L, Peters S, Garon EB, Mok T, POSEIDON investigators
J Clin Oncol. 2023 Feb 20;41(6):1213-1227
Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study.
Girard N, Bar J, Garrido P, Garassino MC, McDonald F, Mornex F, Filippi AR, Smit HJM, Peters S, Field JK, Christoph DC, Sibille A, Fietkau R, Haakensen VD, Chouaid C, Markman B, Hiltermann TJN, Taus A, Sawyer W, Allen A, Chander P, Licour M, Solomon B
J Thorac Oncol. 2023 Feb;18(2):181-193
[Oncology: what's new in 2022].
Nguyen-Ngoc T, Abdelhamid K, Degrauwe N, Galland S, Serena A, Christofis M, Mederos N, Bouchaab H, Diciolla A, Dris N, Orcurto A, Perrinjaquet C, Schnetz M, Latifyan S, Wetterwald L, Herrera Gómez RG, Cristina V, Sarivalasis A, Michielin O, Berthold D, Di
Rev Med Suisse. 2023 Jan 18;19(N° 809-10):52-57
Adherence to the CDK 4/6 Inhibitor Palbociclib and Omission of Dose Management Supported by Pharmacometric Modelling as Part of the OpTAT Study.
Bandiera C, Locatelli I, Courlet P, Cardoso E, Zaman K, Stravodimou A, Dolcan A, Sarivalasis A, Zurcher JP, Aedo-Lopez V, Dotta-Celio J, Peters S, Guidi M, Wagner AD, Csajka C, Schneider MP
Cancers (Basel). 2023 Jan 3;15(1)
Assessment of RANK/RANK-L prevalence and clinical significance in NSCLC European Thoracic Oncology Platform Lungscape cohort and SPLENDOUR randomized clinical trial.
Peters S, Letovanec I, Mauer M, Dafni U, Ejedepang D, Biernat W, Bubendorf L, Warth A, Pokharel S, Reinmuth N, Majem Tarruella M, Casas-Martin J, Tsourti Z, Marti N, Kammler R, Danson S, O'Brien M, Stahel RA
Lung Cancer. 2023 Jan;175:141-151
Safety of First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC: A Pooled Analysis of CheckMate 227, CheckMate 568, and CheckMate 817.
Paz-Ares LG, Ciuleanu TE, Pluzanski A, Lee JS, Gainor JF, Otterson GA, Audigier-Valette C, Ready N, Schenker M, Linardou H, Caro RB, Provencio M, Zurawski B, Lee KH, Kim SW, Caserta C, Ramalingam SS, Spigel DR, Brahmer JR, Reck M, O'Byrne KJ, Girard N, Po
J Thorac Oncol. 2023 Jan;18(1):79-92
A differential process mining analysis of COVID-19 management for cancer patients.
Cuendet MA, Gatta R, Wicky A, Gerard CL, Dalla-Vale M, Tavazzi E, Michielin G, Delyon J, Ferahta N, Cesbron J, Lofek S, Huber A, Jankovic J, Demicheli R, Bouchaab H, Digklia A, Obeid M, Peters S, Eicher M, Pradervand S, Michielin O
Front Oncol. 2022;12:1043675
Expression of phosphorylated ribosomal protein S6 in mesothelioma patients - correlation with clinico-pathological characteristics and outcome: results from the European Thoracic Oncology Platform (ETOP) Mesoscape project.
Rüschoff JH, Haberecker M, Tsourti Z, Nackaerts K, de Perrot M, Brcic L, Nadal E, Tsimpoukis S, Gray SG, Ampollini L, Aerts JG, Felley-Bosco E, Kirschner MB, Monkhorst K, Weynand B, Bavaghar-Zaeimi F, Samarzija M, Llatjos R, Finn SP, Silini E, von der Thü
Mod Pathol. 2022 Dec;35(12):1888-1899
Extended resection for potentially operable patients with stage III non-small cell lung cancer after induction treatment.
Furrer K, Weder W, Eboulet EI, Betticher D, Pless M, Stupp R, Krueger T, Perentes JY, Schmid RA, Lardinois D, Furrer M, Früh M, Peters S, Curioni-Fontecedro A, Stahel RA, Rothschild SI, Hayoz S, Opitz I
J Thorac Cardiovasc Surg. 2022 Dec;164(6):1587-1602.e5
Prognostic impact of tumour mutational burden in resected stage I and II lung adenocarcinomas from a European Thoracic Oncology Platform Lungscape cohort.
Bubendorf L, Zoche M, Dafni U, Rüschoff JH, Prince SS, Marti N, Stavrou A, Kammler R, Finn SP, Moch H, Peters S, Stahel RA
Lung Cancer. 2022 Dec;174:27-35
Correction to: Expression of phosphorylated ribosomal protein S6 in mesothelioma patients - correlation with clinico-pathological characteristics and outcome: results from the European Thoracic Oncology Platform (ETOP) Mesoscape project.
Rüschoff JH, Haberecker M, Tsourti Z, Nackaerts K, de Perrot M, Brcic L, Nadal E, Tsimpoukis S, Gray SG, Ampollini L, Aerts JG, Felley-Bosco E, Kirschner MB, Monkhorst K, Weynand B, Bavaghar-Zaeimi F, Samarzija M, Llatjos R, Finn SP, Silini E, von der Thü
Mod Pathol. 2022 Dec;35(12):2033
Immune checkpoint inhibitor therapy and outcomes from SARS-CoV-2 infection in patients with cancer: a joint analysis of OnCovid and ESMO-CoCARE registries.
Cortellini A, Dettorre GM, Dafni U, Aguilar-Company J, Castelo-Branco L, Lambertini M, Gennatas S, Angelis V, Sita-Lumsden A, Rogado J, Pedrazzoli P, Viñal D, Prat A, Rossi M, Berardi R, Alonso-Gordoa T, Grisanti S, Dimopoulou G, Queirolo P, Pradervand S,
J Immunother Cancer. 2022 Nov;10(11)
Patients' experiences with cancer care in Switzerland: Results of a multicentre cross-sectional survey.
Arditi C, Eicher M, Colomer-Lahiguera S, Bienvenu C, Anchisi S, Betticher D, Dietrich PY, Duchosal M, Peters S, Peytremann-Bridevaux I
Eur J Cancer Care (Engl). 2022 Nov;31(6):e13705
Minus Times Minus Equals Plus.
Haanen J, Peters S
J Clin Oncol. 2022 Oct 10;40(29):3453-3455
Alectinib for the treatment of pretreated RET-rearranged advanced NSCLC: Results of the ETOP ALERT-lung trial.
Felip E, Smit EF, Molina-Vila MA, Dafni U, Massuti B, Berghmans T, de Marinis F, Passiglia F, Dingemans AC, Cobo M, Viteri S, Britschgi C, Cuffe S, Provencio M, Merkelbach-Bruse S, Andriakopoulou C, Kammler R, Ruepp B, Roschitzki-Voser H, Peters S, Wolf J
Lung Cancer. 2022 Oct;172:94-99
Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial.
O'Brien M, Paz-Ares L, Marreaud S, Dafni U, Oselin K, Havel L, Esteban E, Isla D, Martinez-Marti A, Faehling M, Tsuboi M, Lee JS, Nakagawa K, Yang J, Samkari A, Keller SM, Mauer M, Jha N, Stahel R, Besse B, Peters S, EORTC-1416-LCG/ETOP 8-15 – PEARLS/KEYN
Lancet Oncol. 2022 Oct;23(10):1274-1286
First communication on the efficacy of combined (177)Lutetium-PSMA with immunotherapy outside prostate cancer.
Digklia A, Boughdad S, Homicsko K, Dromain C, Trimech M, Dolcan A, Peters S, Prior J, Schaefer N
J Immunother Cancer. 2022 Oct;10(10)
Systematic comparison with autoimmune liver disease identifies specific histological features of immune checkpoint inhibitor-related adverse events.
Coukos A, Vionnet J, Obeid M, Bouchaab H, Peters S, Latifyan S, Wicky A, Michielin O, Chtioui H, Moradpour D, Fasquelle F, Sempoux C, Fraga M
J Immunother Cancer. 2022 Oct;10(10)
Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 2nd - 4th, 2021, Italy).
Ascierto PA, Agarwala SS, Blank C, Caracò C, Carvajal RD, Ernstoff MS, Ferrone S, Fox BA, Gajewski TF, Garbe C, Grob JJ, Hamid O, Krogsgaard M, Lo RS, Lund AW, Madonna G, Michielin O, Neyns B, Osman I, Peters S, Poulikakos PI, Quezada SA, Reinfeld B, Zitv
J Transl Med. 2022 Sep 4;20(1):391
Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial.
Peters S, Dziadziuszko R, Morabito A, Felip E, Gadgeel SM, Cheema P, Cobo M, Andric Z, Barrios CH, Yamaguchi M, Dansin E, Danchaivijitr P, Johnson M, Novello S, Mathisen MS, Shagan SM, Schleifman E, Wang J, Yan M, Mocci S, Voong D, Fabrizio DA, Shames DS,
Nat Med. 2022 Sep;28(9):1831-1839
An International Comparison of Presentation, Outcomes and CORONET Predictive Score Performance in Patients with Cancer Presenting with COVID-19 across Different Pandemic Waves.
Wysocki O, Zhou C, Rogado J, Huddar P, Shotton R, Tivey A, Albiges L, Angelakas A, Arnold D, Aung T, Banfill K, Baxter M, Barlesi F, Bayle A, Besse B, Bhogal T, Boyce H, Britton F, Calles A, Castelo-Branco L, Copson E, Croitoru A, Dani SS, Dickens E, East
Cancers (Basel). 2022 Aug 16;14(16)
Real-world survival outcomes in patients with locally advanced or metastatic NTRK fusion-positive solid tumors receiving standard-of-care therapies other than targeted TRK inhibitors.
Hibar DP, Demetri GD, Peters S, Davies J, Humblet O, Maund SL, Perez L
PLoS One. 2022;17(8):e0270571
Coronavirus Disease 2019 Outcomes, Patient Vaccination Status, and Cancer-Related Delays During the Omicron Wave: A Brief Report From the TERAVOLT Analysis.
Bestvina CM, Whisenant JG, Torri V, Cortellini A, Wakelee H, Peters S, Roca E, De Toma A, Hirsch FR, Mamdani H, Halmos B, Arrieta O, Metivier AC, Fidler MJ, Rogado J, Presley CJ, Mascaux C, Genova C, Blaquier JB, Addeo A, Finocchiaro G, Khan H, Mazieres J
JTO Clin Res Rep. 2022 Aug;3(8):100335
Setting the Benchmark for KRAS(G12C) -Mutated NSCLC.
Passaro A, Peters S
N Engl J Med. 2022 Jul 14;387(2):180-183
Addressing CPI resistance in NSCLC: targeting TAM receptors to modulate the tumor microenvironment and future prospects.
Peters S, Paz-Ares L, Herbst RS, Reck M
J Immunother Cancer. 2022 Jul;10(7)
A prognostic score for patients with malignant pleural mesothelioma (MPM) receiving second-line immunotherapy or chemotherapy in the ETOP 9-15 PROMISE-meso phase III trial.
Banna GL, Addeo A, Zygoura P, Tsourti Z, Popat S, Curioni-Fontecedro A, Nadal E, Shah R, Pope A, Fisher P, Spicer J, Roy A, Gilligan D, Gautschi O, Janthur WD, López-Castro R, Roschitzki-Voser H, Dafni U, Peters S, Stahel RA
Lung Cancer. 2022 Jul;169:77-83
[Occupational cancers: essentials for the general practioners].
Krief P, Cohidon C, Turcu V, Rinaldo M, Kamara M, Koller M, Zyska Cherix A, Senn N, Peters S
Rev Med Suisse. 2022 Jun 29;18(788):1313-1321
[Targeted therapies and non-small cell carcinomas : novelties].
Stauber R, Gro S L, Nguyen-Ngoc T, Mederos N, Bouchaab H, Peters S, Abdelhamid K
Rev Med Suisse. 2022 May 18;18(782):970-975
Circulating Cell-free DNA as a Prognostic Biomarker in Patients with Advanced ALK+ Non-small Cell Lung Cancer in the Global Phase III ALEX Trial.
Dziadziuszko R, Peters S, Mok T, Camidge DR, Gadgeel SM, Ou SI, Konopa K, Noé J, Nowicka M, Bordogna W, Morcos PN, Smoljanovic V, Shaw AT
Clin Cancer Res. 2022 May 2;28(9):1800-1808
Humoral Responses Against Variants of Concern by COVID-19 mRNA Vaccines in Immunocompromised Patients.
Obeid M, Suffiotti M, Pellaton C, Bouchaab H, Cairoli A, Salvadé V, Stevenel C, Hottinger R, Pythoud C, Coutechier L, Molinari L, Trono D, Ribi C, Gottardo R, Fenwick C, Pascual M, Duchosal MA, Peters S, Pantaleo G
JAMA Oncol. 2022 May 1;8(5):e220446
First-line nivolumab plus ipilimumab versus chemotherapy for the treatment of unresectable malignant pleural mesothelioma: patient-reported outcomes in CheckMate 743.
Scherpereel A, Antonia S, Bautista Y, Grossi F, Kowalski D, Zalcman G, Nowak AK, Fujimoto N, Peters S, Tsao AS, Mansfield AS, Popat S, Sun X, Lawrance R, Zhang X, Daumont MJ, Bennett B, McKenna M, Baas P
Lung Cancer. 2022 May;167:8-16
CheckMate 73L: A Phase 3 Study Comparing Nivolumab Plus Concurrent Chemoradiotherapy Followed by Nivolumab With or Without Ipilimumab Versus Concurrent Chemoradiotherapy Followed by Durvalumab for Previously Untreated, Locally Advanced Stage III Non-Small
De Ruysscher D, Ramalingam S, Urbanic J, Gerber DE, Tan DSW, Cai J, Li A, Peters S
Clin Lung Cancer. 2022 May;23(3):e264-e268
A Definitive Prognostication System for Patients With Thoracic Malignancies Diagnosed With Coronavirus Disease 2019: An Update From the TERAVOLT Registry.
Whisenant JG, Baena J, Cortellini A, Huang LC, Lo Russo G, Porcu L, Wong SK, Bestvina CM, Hellmann MD, Roca E, Rizvi H, Monnet I, Boudjemaa A, Rogado J, Pasello G, Leighl NB, Arrieta O, Aujayeb A, Batra U, Azzam AY, Unk M, Azab MA, Zhumagaliyeva AN, Gomez
J Thorac Oncol. 2022 May;17(5):661-674
Establishment of CORONET, COVID-19 Risk in Oncology Evaluation Tool, to Identify Patients With Cancer at Low Versus High Risk of Severe Complications of COVID-19 Disease On Presentation to Hospital.
Lee RJ, Wysocki O, Zhou C, Shotton R, Tivey A, Lever L, Woodcock J, Albiges L, Angelakas A, Arnold D, Aung T, Banfill K, Baxter M, Barlesi F, Bayle A, Besse B, Bhogal T, Boyce H, Britton F, Calles A, Castelo-Branco L, Copson E, Croitoru AE, Dani SS, Dicke
JCO Clin Cancer Inform. 2022 May;6:e2100177
Histological and molecular plasticity of ALK-positive non-small-cell lung cancer under targeted therapy: a case report.
Ball M, Christopoulos P, Kirchner M, Allgäuer M, Brandt R, Winter H, Heußel CP, Herth F, Fröhling S, Savai R, Kriegsmann M, Schirmacher P, Peters S, Thomas M, Stenzinger A, Kazdal D
Cold Spring Harb Mol Case Stud. 2022 Apr;8(3)
Delayed Diagnosis of Lung Carcinoma Presenting as Choroidal Metastasis in a COVID-19 Patient and Initially Treated with Osimertinib.
Haeller CN, Khamsy L, Kloepper J, Schiappacasse L, Bouchaab H, Peters S, Schalenbourg A
Klin Monbl Augenheilkd. 2022 Apr;239(4):586-589
Efficacy of targeted therapies for oncogene-driven lung cancer in early single-arm versus late phase randomized clinical trials: A comparative analysis.
Tan AC, Tan SH, Zhou S, Peters S, Curigliano G, Tan DSW
Cancer Treat Rev. 2022 Mar;104:102354
Managing Resistance to Immune Checkpoint Inhibitors in Lung Cancer: Treatment and Novel Strategies.
Passaro A, Brahmer J, Antonia S, Mok T, Peters S
J Clin Oncol. 2022 Feb 20;40(6):598-610
[2021 Oncology update].
Meyer ML, Chrysou K, Stamatiou A, Gilabert M, Herrera Gomez RG, Latifyan S, Masmoudi S, Mederos N, Perrinjaquet C, Berthold D, Bouchaab H, Cristina V, Digklia A, Michielin O, Orcurto A, Sarivalasis A, Stravodimou A, Wagner AD, Zaman K, Peters S, Jankovic
Rev Med Suisse. 2022 Feb 2;18(767):182-186
Deciphering the immunosuppressive tumor microenvironment in ALK- and EGFR-positive lung adenocarcinoma.
Budczies J, Kirchner M, Kluck K, Kazdal D, Glade J, Allgäuer M, Kriegsmann M, Heußel CP, Herth FJ, Winter H, Meister M, Muley T, Goldmann T, Fröhling S, Wermke M, Waller CF, Tufman A, Reck M, Peters S, Schirmacher P, Thomas M, Christopoulos P, Stenzinger
Cancer Immunol Immunother. 2022 Feb;71(2):251-265
Targeting HER2-Mutant NSCLC - The Light Is On.
Passaro A, Peters S
N Engl J Med. 2022 Jan 20;386(3):286-289
Evaluation of atezolizumab immunogenicity: Efficacy and safety (Part 2).
Peters S, Galle PR, Bernaards CA, Ballinger M, Bruno R, Quarmby V, Ruppel J, Vilimovskij A, Wu B, Sternheim N, Reck M
Clin Transl Sci. 2022 Jan;15(1):141-157
Defining unique clinical hallmarks for immune checkpoint inhibitor-based therapies.
Michielin O, Lalani AK, Robert C, Sharma P, Peters S
J Immunother Cancer. 2022 Jan;10(1)
COVID-19 and Cancer: A Review of the Registry-Based Pandemic Response.
Desai A, Mohammed TJ, Duma N, Garassino MC, Hicks LK, Kuderer NM, Lyman GH, Mishra S, Pinato DJ, Rini BI, Peters S, Warner JL, Whisenant JG, Wood WA, Thompson MA
JAMA Oncol. 2021 Dec 1;7(12):1882-1890
Blood First Assay Screening Trial (BFAST) in Treatment-Naive Advanced or Metastatic NSCLC: Initial Results of the Phase 2 ALK-Positive Cohort.
Dziadziuszko R, Mok T, Peters S, Han JY, Alatorre-Alexander J, Leighl N, Sriuranpong V, Pérol M, de Castro Junior G, Nadal E, de Marinis F, Frontera OA, Tan DSW, Lee DH, Kim HR, Yan M, Riehl T, Schleifman E, Paul SM, Mocci S, Patel R, Assaf ZJ, Shames DS,
J Thorac Oncol. 2021 Dec;16(12):2040-2050
Early discharge after thoracoscopic anatomical pulmonary resection for non-small-cell lung cancer.
Forster C, Perentes JY, Ojanguren A, Abdelnour-Berchtold E, Zellweger M, Bouchaab H, Peters S, Krueger T, Gonzalez M
Interact Cardiovasc Thorac Surg. 2021 Nov 22;33(6):892-898
Combined, patient-level, analysis of two randomised trials evaluating the addition of denosumab to standard first-line chemotherapy in advanced NSCLC - The ETOP/EORTC SPLENDOUR and AMGEN-249 trials.
Peters S, Danson S, Ejedepang D, Dafni U, Hasan B, Radcliffe HS, Bustin F, Crequit J, Coate L, Guillot M, Surmont V, Rauch D, Rudzki J, O'Mahony D, Barneto Aranda I, Scherz A, Tsourti Z, Roschitzki-Voser H, Pochesci A, Demonty G, Stahel RA, O'Brien M
Lung Cancer. 2021 Nov;161:76-85
Pilot Testing of a Nurse-Led Basic Symptom Self-management Support for Patients Receiving First-Line Systemic Outpatient Anticancer Treatment: A Cluster-Randomized Study (Symptom Navi Pilot Study).
Bana M, Ribi K, Peters S, Kropf-Staub S, Näf E, Zürcher-Florin S, Stoffel B, Blaeuer C, Borner M, Malin D, Biber R, Betticher D, Kuhn-Bächler T, Cantoni N, Seeger T, Bütikofer L, Eicher M, Symptom Navi Program Group
Cancer Nurs. 2021 Nov-Dec 01;44(6):E687-E702
Quantification of the spatial distribution of primary tumors in the lung to develop new prognostic biomarkers for locally advanced NSCLC.
Vuong D, Bogowicz M, Wee L, Riesterer O, Vlaskou Badra E, D'Cruz LA, Balermpas P, van Timmeren JE, Burgermeister S, Dekker A, De Ruysscher D, Unkelbach J, Thierstein S, Eboulet EI, Peters S, Pless M, Guckenberger M, Tanadini-Lang S
Sci Rep. 2021 Oct 22;11(1):20890
(68)Ga-DOTATOC PET/CT to detect immune checkpoint inhibitor-related myocarditis.
Boughdad S, Latifyan S, Fenwick C, Bouchaab H, Suffiotti M, Moslehi JJ, Salem JE, Schaefer N, Nicod-Lalonde M, Costes J, Perreau M, Michielin O, Peters S, Prior JO, Obeid M
J Immunother Cancer. 2021 Oct;9(10)
The CoVID-TE risk assessment model for venous thromboembolism in hospitalized patients with cancer and COVID-19.
Li A, Kuderer NM, Hsu CY, Shyr Y, Warner JL, Shah DP, Kumar V, Shah S, Kulkarni AA, Fu J, Gulati S, Zon RL, Li M, Desai A, Egan PC, Bakouny Z, Kc D, Hwang C, Akpan IJ, McKay RR, Girard J, Schmidt AL, Halmos B, Thompson MA, Patel JM, Pennell NA, Peters S,
J Thromb Haemost. 2021 Oct;19(10):2522-2532
SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer-A Multicenter Single-Arm Phase II Trial.
Rothschild SI, Zippelius A, Eboulet EI, Savic Prince S, Betticher D, Bettini A, Früh M, Joerger M, Lardinois D, Gelpke H, Mauti LA, Britschgi C, Weder W, Peters S, Mark M, Cathomas R, Ochsenbein AF, Janthur WD, Waibel C, Mach N, Froesch P, Buess M, Bohane
J Clin Oncol. 2021 Sep 10;39(26):2872-2880
Imaging Features of Pulmonary Immune-related Adverse Events.
Pozzessere C, Lazor R, Jumeau R, Peters S, Prior JO, Beigelman-Aubry C
J Thorac Oncol. 2021 Sep;16(9):1449-1460
Preselection of robust radiomic features does not improve outcome modelling in non-small cell lung cancer based on clinical routine FDG-PET imaging.
Oliveira C, Amstutz F, Vuong D, Bogowicz M, Hüllner M, Foerster R, Basler L, Schröder C, Eboulet EI, Pless M, Thierstein S, Peters S, Hillinger S, Tanadini-Lang S, Guckenberger M
EJNMMI Res. 2021 Aug 21;11(1):79
Neutrophils in the era of immune checkpoint blockade.
Faget J, Peters S, Quantin X, Meylan E, Bonnefoy N
J Immunother Cancer. 2021 Jul;9(7)
Patient-Reported Outcomes with Durvalumab With or Without Tremelimumab Versus Standard Chemotherapy as First-Line Treatment of Metastatic Non-Small-Cell Lung Cancer (MYSTIC).
Garon EB, Cho BC, Reinmuth N, Lee KH, Luft A, Ahn MJ, Robinet G, Le Moulec S, Natale R, Schneider J, Shepherd FA, Garassino MC, Geater SL, Szekely ZP, Van Ngoc T, Liu F, Scheuring U, Patel N, Peters S, Rizvi NA
Clin Lung Cancer. 2021 Jul;22(4):301-312.e8
Optimizing Oral Targeted Anticancer Therapies Study for Patients With Solid Cancer: Protocol for a Randomized Controlled Medication Adherence Program Along With Systematic Collection and Modeling of Pharmacokinetic and Pharmacodynamic Data.
Bandiera C, Cardoso E, Locatelli I, Digklia A, Zaman K, Diciolla A, Cristina V, Stravodimou A, Veronica AL, Dolcan A, Sarivalasis A, Liapi A, Bouchaab H, Orcurto A, Dotta-Celio J, Peters S, Decosterd L, Widmer N, Wagner D, Csajka C, Schneider MP
JMIR Res Protoc. 2021 Jun 29;10(6):e30090
Lurbinectedin in Refractory Diffuse Malignant Peritoneal Mesothelioma: Report of Two Cases.
Gros L, Szturz P, Diciolla A, Kirchner V, Peters S, Schaefer N, Hubner M, Digklia A
Front Oncol. 2021;11:704295
Nongenetic Evolution Drives Lung Adenocarcinoma Spatial Heterogeneity and Progression.
Tavernari D, Battistello E, Dheilly E, Petruzzella AS, Mina M, Sordet-Dessimoz J, Peters S, Krueger T, Gfeller D, Riggi N, Oricchio E, Letovanec I, Ciriello G
Cancer Discov. 2021 Jun;11(6):1490-1507
Treatment Decisions for Patients with Cancer during the COVID-19 Pandemic.
Labaki C, Peters S, Choueiri TK
Cancer Discov. 2021 Jun;11(6):1330-1335
Prognostic Impact of KRAS G12C Mutation in Patients With NSCLC: Results From the European Thoracic Oncology Platform Lungscape Project.
Finn SP, Addeo A, Dafni U, Thunnissen E, Bubendorf L, Madsen LB, Biernat W, Verbeken E, Hernandez-Losa J, Marchetti A, Cheney R, Warth A, Speel EM, Quinn AM, Monkhorst K, Jantus-Lewintre E, Tischler V, Marti N, Dimopoulou G, Molina-Vila MA, Kammler R, Ker
J Thorac Oncol. 2021 Jun;16(6):990-1002
Oncologie et pandémie de Covid-19 : les patients au cœur des enjeux.
Dietrich PY, Aapro M, Peters S
Rev Med Suisse. 2021 May 19;17(739):955
Recent Advances on the Role of EGFR Tyrosine Kinase Inhibitors in the Management of NSCLC With Uncommon, Non Exon 20 Insertions, EGFR Mutations.
Passaro A, Mok T, Peters S, Popat S, Ahn MJ, de Marinis F
J Thorac Oncol. 2021 May;16(5):764-773
GLUT1 Expression in Tumor-Associated Neutrophils Promotes Lung Cancer Growth and Resistance to Radiotherapy.
Ancey PB, Contat C, Boivin G, Sabatino S, Pascual J, Zangger N, Perentes JY, Peters S, Abel ED, Kirsch DG, Rathmell JC, Vozenin MC, Meylan E
Cancer Res. 2021 May 1;81(9):2345-2357
Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451.
Owonikoko TK, Park K, Govindan R, Ready N, Reck M, Peters S, Dakhil SR, Navarro A, Rodríguez-Cid J, Schenker M, Lee JS, Gutierrez V, Percent I, Morgensztern D, Barrios CH, Greillier L, Baka S, Patel M, Lin WH, Selvaggi G, Baudelet C, Baden J, Pandya D, Do
J Clin Oncol. 2021 Apr 20;39(12):1349-1359
[Telephone follow-up of SARS-CoV-2 positive patients at the Oncology Department of Lausanne University Hospital].
Jankovic J, Da Silva Lopes AM, Morez A, Darnac C, Demicheli R, Dalla-Vale M, Lauriers N, Garcia Sanchez J, Bouchaab H, Ninane F, Peters S, Michielin O, Pradervand S, Eicher M, Colomer-Lahiguera S
Rev Med Suisse. 2021 Apr 7;17(733):703-707
Overcoming therapy resistance in EGFR-mutant lung cancer.
Passaro A, Jänne PA, Mok T, Peters S
Nat Cancer. 2021 Apr;2(4):377-391
The Promising Evolution of Targeted Therapeutic Strategies in Cancer.
Peters S, Mok T, Passaro A, Jänne PA
Cancer Discov. 2021 Apr;11(4):810-814
OncoAlert Round Table Discussions: The Global COVID-19 Experience.
Morgan G, de Azambuja E, Punie K, Ades F, Heinrich K, Personeni N, Rahme R, Ferrara R, Pels K, Garassino M, von Bergwelt-Baildon M, Lopes G, Barlesi F, Choueiri TK, Burris H, Peters S
JCO Glob Oncol. 2021 Apr;7:455-463
Conventional and semi-automatic histopathological analysis of tumor cell content for multigene sequencing of lung adenocarcinoma.
Kazdal D, Rempel E, Oliveira C, Allgäuer M, Harms A, Singer K, Kohlwes E, Ormanns S, Fink L, Kriegsmann J, Leichsenring M, Kriegsmann K, Stögbauer F, Tavernar L, Leichsenring J, Volckmar AL, Longuespée R, Winter H, Eichhorn M, Heußel CP, Herth F, Christop
Transl Lung Cancer Res. 2021 Apr;10(4):1666-1678
A Blood-based Assay for Assessment of Tumor Mutational Burden in First-line Metastatic NSCLC Treatment: Results from the MYSTIC Study.
Si H, Kuziora M, Quinn KJ, Helman E, Ye J, Liu F, Scheuring U, Peters S, Rizvi NA, Brohawn PZ, Ranade K, Higgs BW, Banks KC, Chand VK, Raja R
Clin Cancer Res. 2021 Mar 15;27(6):1631-1640
Fast progression in non-small cell lung cancer: results from the randomized phase III OAK study evaluating second-line atezolizumab versus docetaxel.
Gandara D, Reck M, Moro-Sibilot D, Mazieres J, Gadgeel S, Morris S, Cardona A, Mendus D, Ballinger M, Rittmeyer A, Peters S
J Immunother Cancer. 2021 Mar;9(3)
Severity of COVID-19 in patients with lung cancer: evidence and challenges.
Passaro A, Bestvina C, Velez Velez M, Garassino MC, Garon E, Peters S
J Immunother Cancer. 2021 Mar;9(3)
Strength in numbers: predicting response to checkpoint inhibitors from large clinical datasets.
Stenzinger A, Kazdal D, Peters S
Cell. 2021 Feb 4;184(3):571-573
Outcomes According to ALK Status Determined by Central Immunohistochemistry or Fluorescence In Situ Hybridization in Patients With ALK-Positive NSCLC Enrolled in the Phase 3 ALEX Study.
Mok T, Peters S, Camidge DR, Noé J, Gadgeel S, Ou SI, Kim DW, Konopa K, Pozzi E, Liu T, Loftin IR, Williams C, Shaw AT
J Thorac Oncol. 2021 Feb;16(2):259-268
Progression-Free and Overall Survival for Concurrent Nivolumab With Standard Concurrent Chemoradiotherapy in Locally Advanced Stage IIIA-B NSCLC: Results From the European Thoracic Oncology Platform NICOLAS Phase II Trial (European Thoracic Oncology Platf
Peters S, Felip E, Dafni U, Tufman A, Guckenberger M, Álvarez R, Nadal E, Becker A, Vees H, Pless M, Martinez-Marti A, Lambrecht M, Andratschke N, Tsourti Z, Piguet AC, Roschitzki-Voser H, Gasca-Ruchti A, Vansteenkiste J, Stahel RA, De Ruysscher D
J Thorac Oncol. 2021 Feb;16(2):278-288
Personalized Cytokine-Directed Therapy With Tocilizumab for Refractory Immune Checkpoint Inhibitor-Related Cholangiohepatitis.
Moi L, Bouchaab H, Mederos N, Nguyen-Ngoc T, Perreau M, Fenwick C, Vaucher J, Sempoux C, Peters S, Obeid M
J Thorac Oncol. 2021 Feb;16(2):318-326
First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial.
Baas P, Scherpereel A, Nowak AK, Fujimoto N, Peters S, Tsao AS, Mansfield AS, Popat S, Jahan T, Antonia S, Oulkhouir Y, Bautista Y, Cornelissen R, Greillier L, Grossi F, Kowalski D, Rodríguez-Cid J, Aanur P, Oukessou A, Baudelet C, Zalcman G
Lancet. 2021 Jan 30;397(10272):375-386
[2020 oncology update].
Dei Tos G, Galli Vareia I, Huber A, Wolf B, Diciolla A, Herrera Gomez RG, Wagner D, Digklia A, Bouchaab H, Cristina V, Stravodimou A, Zaman K, Sarivalasis A, Berthold D, Peters S, Perrinjaquet C, Kloepper J, Jankovic J
Rev Med Suisse. 2021 Jan 27;17(723):201-205
A gene expression signature associated with B cells predicts benefit from immune checkpoint blockade in lung adenocarcinoma.
Budczies J, Kirchner M, Kluck K, Kazdal D, Glade J, Allgäuer M, Kriegsmann M, Heußel CP, Herth FJ, Winter H, Meister M, Muley T, Fröhling S, Peters S, Seliger B, Schirmacher P, Thomas M, Christopoulos P, Stenzinger A
Oncoimmunology. 2021 Jan 11;10(1):1860586
Impact of an enhanced recovery after surgery pathway on thoracoscopic lobectomy outcomes in non-small cell lung cancer patients: a propensity score-matched study.
Forster C, Doucet V, Perentes JY, Abdelnour-Berchtold E, Zellweger M, Faouzi M, Bouchaab H, Peters S, Marcucci C, Krueger T, Rosner L, Gonzalez M
Transl Lung Cancer Res. 2021 Jan;10(1):93-103
Abscopal effect in a patient with malignant pleural mesothelioma treated with palliative radiotherapy and pembrolizumab.
Mampuya WA, Bouchaab H, Schaefer N, Kinj R, La Rosa S, Letovanec I, Ozsahin M, Bourhis J, Coukos G, Peters S, Herrera FG
Clin Transl Radiat Oncol. 2021 Mar;27:85-88
Targeting KRAS-Mutant Non-Small-Cell Lung Cancer: One Mutation at a Time, With a Focus on KRAS G12C Mutations.
Burns TF, Borghaei H, Ramalingam SS, Mok TS, Peters S
J Clin Oncol. 2020 Dec 10;38(35):4208-4218
Radiomics Feature Activation Maps as a New Tool for Signature Interpretability.
Vuong D, Tanadini-Lang S, Wu Z, Marks R, Unkelbach J, Hillinger S, Eboulet EI, Thierstein S, Peters S, Pless M, Guckenberger M, Bogowicz M
Front Oncol. 2020;10:578895
Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment.
Subbiah V, Paz-Ares L, Besse B, Moreno V, Peters S, Sala MA, López-Vilariño JA, Fernández C, Kahatt C, Alfaro V, Siguero M, Zeaiter A, Zaman K, López R, Ponce S, Boni V, Arrondeau J, Delord JP, Martínez M, Wannesson L, Antón A, Valdivia J, Awada A, Kriste
Lung Cancer. 2020 Dec;150:90-96
Impact of COVID-19 on cancer service delivery: results from an international survey of oncology clinicians.
Chazan G, Franchini F, Alexander M, Banerjee S, Mileshkin L, Blinman P, Zielinski R, Karikios D, Pavlakis N, Peters S, Lordick F, Ball D, Wright G, I Jzerman M, Solomon B
ESMO Open. 2020 Dec;5(6):e001090
[Lung cancer screening in Switzerland : Who ? How ? When ?].
Casutt A, Lovis A, Selby K, Noirez L, Peters S, Beigelman-Aubry C, Krueger T, Soccal PM, Von Garnier C
Rev Med Suisse. 2020 Nov 18;16(715):2224-2226
The METeoric rise of MET in lung cancer.
Friedlaender A, Drilon A, Banna GL, Peters S, Addeo A
Cancer. 2020 Nov 15;126(22):4826-4837
COVID-19 and Cancer: Current Challenges and Perspectives.
Bakouny Z, Hawley JE, Choueiri TK, Peters S, Rini BI, Warner JL, Painter CA
Cancer Cell. 2020 Nov 9;38(5):629-646
Tumor Mutational Burden as a Pan-cancer Biomarker for Immunotherapy: The Limits and Potential for Convergence.
Passaro A, Stenzinger A, Peters S
Cancer Cell. 2020 Nov 9;38(5):624-625
Supporting Clinical Decision-Making during the SARS-CoV-2 Pandemic through a Global Research Commitment: The TERAVOLT Experience.
Trama A, Proto C, Whisenant JG, Torri V, Cortellini A, Michielin O, Barlesi F, Dingemans AC, Van Meerbeeck J, Pancaldi V, Mazieres J, Soo RA, Leighl NB, Peters S, Wakelee H, Horn L, Hellmann M, Wong SK, Garassino MC, Baena J
Cancer Cell. 2020 Nov 9;38(5):602-604
[Lung cancer screening: what can we tell our patients while we await a screening program ?].
Selby K, Gubelmann R, Lovis A, Bulliard JL, Beigelman-Aubry C, Casutt A, Peters S, Krueger T, Von Garnier C, Cornuz J
Rev Med Suisse. 2020 Nov 4;16(713):2086-2091
Gender-specific aspects of epidemiology, molecular genetics and outcome: lung cancer.
Mederos N, Friedlaender A, Peters S, Addeo A
ESMO Open. 2020 Nov;5(Suppl 4):e000796
Outcomes According to ALK Status Determined by Central IHC or FISH in Patients with ALK-Positive NSCLC Enrolled in the Phase III ALEX Study.
Mok T, Peters S, Camidge DR, Noé J, Gadgeel S, Ignatius Ou SH, Kim DW, Konopa K, Pozzi E, Liu T, Loftin IR, Williams C, Shaw AT
J Thorac Oncol. 2020 Oct 24
A Randomized Open-Label Phase III Trial Evaluating the Addition of Denosumab to Standard First-Line Treatment in Advanced NSCLC: The European Thoracic Oncology Platform (ETOP) and European Organisation for Research and Treatment of Cancer (EORTC) SPLENDOU
Peters S, Danson S, Hasan B, Dafni U, Reinmuth N, Majem M, Tournoy KG, Mark MT, Pless M, Cobo M, Rodriguez-Abreu D, Falchero L, Moran T, Ortega Granados AL, Monnet I, Mohorcic K, Sureda BM, Betticher D, Demedts I, Macias JA, Cuffe S, Luciani A, Sanchez JG
J Thorac Oncol. 2020 Oct;15(10):1647-1656
Utilization of COVID-19 Treatments and Clinical Outcomes among Patients with Cancer: A COVID-19 and Cancer Consortium (CCC19) Cohort Study.
Rivera DR, Peters S, Panagiotou OA, Shah DP, Kuderer NM, Hsu CY, Rubinstein SM, Lee BJ, Choueiri TK, de Lima Lopes G Jr, Grivas P, Painter CA, Rini BI, Thompson MA, Arcobello J, Bakouny Z, Doroshow DB, Egan PC, Farmakiotis D, Fecher LA, Friese CR, Galsky
Cancer Discov. 2020 Oct;10(10):1514-1527
Comparison of robust to standardized CT radiomics models to predict overall survival for non-small cell lung cancer patients.
Vuong D, Bogowicz M, Denzler S, Oliveira C, Foerster R, Amstutz F, Gabryś HS, Unkelbach J, Hillinger S, Thierstein S, Xyrafas A, Peters S, Pless M, Guckenberger M, Tanadini-Lang S
Med Phys. 2020 Sep;47(9):4045-4053
The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology Committee.
Sholl LM, Hirsch FR, Hwang D, Botling J, Lopez-Rios F, Bubendorf L, Mino-Kenudson M, Roden AC, Beasley MB, Borczuk A, Brambilla E, Chen G, Chou TY, Chung JH, Cooper WA, Dacic S, Lantuejoul S, Jain D, Lin D, Minami Y, Moreira A, Nicholson AG, Noguchi M, Pa
J Thorac Oncol. 2020 Sep;15(9):1409-1424
Survey of the Impact of COVID-19 on Oncologists' Decision Making in Cancer.
Ürün Y, Hussain SA, Bakouny Z, Castellano D, Kılıçkap S, Morgan G, Mckay RR, Pels K, Schmidt A, Doroshow DB, Schütz F, Albiges L, Lopes G, Catto JWF, Peters S, Choueiri TK
JCO Glob Oncol. 2020 Aug;6:1248-1257
Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study.
Rudin CM, Awad MM, Navarro A, Gottfried M, Peters S, Csőszi T, Cheema PK, Rodriguez-Abreu D, Wollner M, Yang JC, Mazieres J, Orlandi FJ, Luft A, Gümüş M, Kato T, Kalemkerian GP, Luo Y, Ebiana V, Pietanza MC, Kim HR, KEYNOTE-604 Investigators
J Clin Oncol. 2020 Jul 20;38(21):2369-2379
Gender gap: surveying the world for tomorrow.
Garrido P, Tsang J, Peters S
ESMO Open. 2020 Jul;5(4)
Treatment Guidance for Patients With Lung Cancer During the Coronavirus 2019 Pandemic.
Dingemans AC, Soo RA, Jazieh AR, Rice SJ, Kim YT, Teo LLS, Warren GW, Xiao SY, Smit EF, Aerts JG, Yoon SH, Veronesi G, De Cobelli F, Ramalingam SS, Garassino MC, Wynes MW, Behera M, Haanen J, Lu S, Peters S, Ahn MJ, Scagliotti GV, Adjei AA, Belani CP
J Thorac Oncol. 2020 Jul;15(7):1119-1136
COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study.
Garassino MC, Whisenant JG, Huang LC, Trama A, Torri V, Agustoni F, Baena J, Banna G, Berardi R, Bettini AC, Bria E, Brighenti M, Cadranel J, De Toma A, Chini C, Cortellini A, Felip E, Finocchiaro G, Garrido P, Genova C, Giusti R, Gregorc V, Grossi F, Gro
Lancet Oncol. 2020 Jul;21(7):914-922
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study.
Kuderer NM, Choueiri TK, Shah DP, Shyr Y, Rubinstein SM, Rivera DR, Shete S, Hsu CY, Desai A, de Lima Lopes G Jr, Grivas P, Painter CA, Peters S, Thompson MA, Bakouny Z, Batist G, Bekaii-Saab T, Bilen MA, Bouganim N, Larroya MB, Castellano D, Del Prete SA
Lancet. 2020 Jun 20;395(10241):1907-1918
The COVID-19 and Cancer Consortium: A Collaborative Effort to Understand the Effects of COVID-19 on Patients with Cancer.
Rubinstein SM, Steinharter JA, Warner J, Rini BI, Peters S, Choueiri TK
Cancer Cell. 2020 Jun 8;37(6):738-741
TERAVOLT: Thoracic Cancers International COVID-19 Collaboration.
Whisenant JG, Trama A, Torri V, De Toma A, Viscardi G, Cortellini A, Michielin O, Barlesi F, Dingemans AC, Van Meerbeeck J, Pancaldi V, Soo RA, Leighl NB, Peters S, Wakelee H, Garassino MC, Horn L
Cancer Cell. 2020 Jun 8;37(6):742-745
Impact of lorlatinib on patient-reported outcomes in patients with advanced ALK-positive or ROS1-positive non-small cell lung cancer.
Peters S, Shaw AT, Besse B, Felip E, Solomon BJ, Soo RA, Bearz A, Gadgeel SM, Lin CC, Kao S, Seto T, Masters ET, Abbattista A, Clancy JS, Thurm H, Reisman A, Peltz G, Ross Camidge D
Lung Cancer. 2020 Jun;144:10-19
Challenges in lung cancer therapy during the COVID-19 pandemic.
Calabrò L, Peters S, Soria JC, Di Giacomo AM, Barlesi F, Covre A, Altomonte M, Vegni V, Gridelli C, Reck M, Rizvi N, Maio M
Lancet Respir Med. 2020 Jun;8(6):542-544
Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: review of the literature and suggested prophylactic strategy.
Haanen J, Ernstoff M, Wang Y, Menzies A, Puzanov I, Grivas P, Larkin J, Peters S, Thompson J, Obeid M
J Immunother Cancer. 2020 Jun;8(1)
ESMO Management and treatment adapted recommendations in the COVID-19 era: Lung cancer.
Passaro A, Addeo A, Von Garnier C, Blackhall F, Planchard D, Felip E, Dziadziuszko R, de Marinis F, Reck M, Bouchaab H, Peters S
ESMO Open. 2020 Jun;5(Suppl 3)
Une période de craintes et de défis : vers un monde meilleur ?
Dietrich PY, Aapro M, Peters S
Rev Med Suisse. 2020 May 27;16(695):1071-1072
[Small-cell lung cancer: management and novelties].
Abdelhamid K, Kakourou A, Degrauwe N, Nikolopoulou A, Bouchaab H, Peters S, Nguyen-Ngoc T, Mederos N
Rev Med Suisse. 2020 May 27;16(695):1079-1085
Describing adverse events in Swiss hospitalized oncology patients using the Global Trigger Tool.
Gerber A, Da Silva Lopes A, Szüts N, Simon M, Ribordy-Baudat V, Ebneter A, Perrinjaquet C, Gaignard ME, Nicodet D, Betticher D, Bula G, Cote M, Duchosal MA, Berret PA, Dietrich PY, Brennan C, Decosterd S, Ferreira Nobre S, Peters S, Koelliker R, Ninane F,
Health Sci Rep. 2020 Jun;3(2):e160
Programmed death-ligand 1 expression influenced by tissue sample size. Scoring based on tissue microarrays' and cross-validation with resections, in patients with, stage I-III, non-small cell lung carcinoma of the European Thoracic Oncology Platform Lungs
Thunnissen E, Kerr KM, Dafni U, Bubendorf L, Finn SP, Soltermann A, Biernat W, Cheney R, Verbeken E, Warth A, Marchetti A, Speel EM, Pokharel S, Quinn AM, Monkhorst K, Navarro A, Madsen LB, Tsourti Z, Geiger T, Kammler R, Peters S, Stahel RA, European Tho
Mod Pathol. 2020 May;33(5):792-801
Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial.
Trigo J, Subbiah V, Besse B, Moreno V, López R, Sala MA, Peters S, Ponce S, Fernández C, Alfaro V, Gómez J, Kahatt C, Zeaiter A, Zaman K, Boni V, Arrondeau J, Martínez M, Delord JP, Awada A, Kristeleit R, Olmedo ME, Wannesson L, Valdivia J, Rubio MJ, Anto
Lancet Oncol. 2020 May;21(5):645-654
Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial.
Rizvi NA, Cho BC, Reinmuth N, Lee KH, Luft A, Ahn MJ, van den Heuvel MM, Cobo M, Vicente D, Smolin A, Moiseyenko V, Antonia SJ, Le Moulec S, Robinet G, Natale R, Schneider J, Shepherd FA, Geater SL, Garon EB, Kim ES, Goldberg SB, Nakagawa K, Raja R, Higgs
JAMA Oncol. 2020 May 1;6(5):661-674
[Oncology: navigating the COVID-19 Pandemic and Steer the Course].
Zimmermann S, Dietrich PY, Michielin O, Betticher D, Peters S
Rev Med Suisse. 2020 Apr 29;16(N° 691-2):819-822
Quantifying potential confounders of panel-based tumor mutational burden (TMB) measurement.
Budczies J, Kazdal D, Allgäuer M, Christopoulos P, Rempel E, Pfarr N, Weichert W, Fröhling S, Thomas M, Peters S, Endris V, Schirmacher P, Stenzinger A
Lung Cancer. 2020 Apr;142:114-119
Relationship between pneumonitis induced by immune checkpoint inhibitors and the underlying parenchymal status: a retrospective study.
Pozzessere C, Bouchaab H, Jumeau R, Letovanec I, Daccord C, Bourhis J, Prior JO, Peters S, Lazor R, Beigelman-Aubry C
ERJ Open Res. 2020 Jan;6(1)
Evolution and Clinical Impact of EGFR Mutations in Circulating Free DNA in the BELIEF Trial.
Molina-Vila MA, Stahel RA, Dafni U, Jordana-Ariza N, Balada-Bel A, Garzón-Ibáñez M, García-Peláez B, Mayo-de-Las-Casas C, Felip E, Curioni Fontecedro A, Gautschi O, Peters S, Massutí B, Palmero R, Ponce Aix S, Carcereny E, Früh M, Pless M, Popat S, Cuffe
J Thorac Oncol. 2020 Mar;15(3):416-425
Targeting MET in EGFR resistance in non-small-cell lung cancer-ready for daily practice?
Schmid S, Früh M, Peters S
Lancet Oncol. 2020 Mar;21(3):320-322
Journée du cancer : mobiliser autour de la prévention.
Peters S, Dietrich PY
Rev Med Suisse. 2020 Feb 19;16(682):382-383
Development and implementation strategies of a nurse-led symptom self-management program in outpatient cancer centres: The Symptom Navi© Programme.
Bana M, Ribi K, Kropf-Staub S, Näf E, Schramm MS, Zürcher-Florin S, Peters S, Eicher M
Eur J Oncol Nurs. 2020 Feb;44:101714
[Advances in Oncology 2019].
Vernadou A, Ferahta N, Mederos N, Ferraro D, Dischl-Antonioni I, Diciolla A, Liapi A, Mosimann V, Latifyan S, Aedo-Lopez V, Berthold D, Digklia A, Michielin O, Montemurro M, Wagner AD, Zaman K, Peters S, Stravodimou A, Sarivalasis A
Rev Med Suisse. 2020 Jan 15;16(676-7):72-77
Primary Care-Led Transition Clinics Hold Promise in Improving Care Transitions for Cancer Patients Facing Social Disparities: A Commentary.
Malebranche M, Sarivalasis A, Peters S, Mathevet P, Cornuz J, Bodenmann P
J Prim Care Community Health. 2020 Jan-Dec;11:2150132720957455
Multiple nivolumab-induced CNS demyelination with spontaneous resolution in an asymptomatic metastatic melanoma patient.
Pillonel V, Dunet V, Hottinger AF, Berthod G, Schiappacasse L, Peters S, Michielin O, Aedo-Lopez V
J Immunother Cancer. 2019 Dec 2;7(1):336
Definition of Synchronous Oligometastatic Non-Small Cell Lung Cancer-A Consensus Report.
Dingemans AC, Hendriks LEL, Berghmans T, Levy A, Hasan B, Faivre-Finn C, Giaj-Levra M, Giaj-Levra N, Girard N, Greillier L, Lantuéjoul S, Edwards J, O'Brien M, Reck M, Smit EF, Van Schil P, Postmus PE, Ramella S, Lievens Y, Gaga M, Peled N, Scagliotti GV,
J Thorac Oncol. 2019 Dec;14(12):2109-2119
Patient-reported outcomes from the randomized phase III ALEX study of alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer.
Pérol M, Pavlakis N, Levchenko E, Platania M, Oliveira J, Novello S, Chiari R, Moran T, Mitry E, Nüesch E, Liu T, Balas B, Konopa K, Peters S
Lung Cancer. 2019 Dec;138:79-87
Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.
Hellmann MD, Paz-Ares L, Bernabe Caro R, Zurawski B, Kim SW, Carcereny Costa E, Park K, Alexandru A, Lupinacci L, de la Mora Jimenez E, Sakai H, Albert I, Vergnenegre A, Peters S, Syrigos K, Barlesi F, Reck M, Borghaei H, Brahmer JR, O'Byrne KJ, Geese WJ,
N Engl J Med. 2019 Nov 21;381(21):2020-2031
Spatial and Temporal Heterogeneity of Panel-Based Tumor Mutational Burden in Pulmonary Adenocarcinoma: Separating Biology From Technical Artifacts.
Kazdal D, Endris V, Allgäuer M, Kriegsmann M, Leichsenring J, Volckmar AL, Harms A, Kirchner M, Kriegsmann K, Neumann O, Brandt R, Talla SB, Rempel E, Ploeger C, von Winterfeld M, Christopoulos P, Merino DM, Stewart M, Allen J, Bischoff H, Meister M, Mule
J Thorac Oncol. 2019 Nov;14(11):1935-1947
Appraising the Tail of the Survival Curve in the Era of PD-1/PD-L1 Checkpoint Blockade.
Zimmermann S, Peters S
JAMA Oncol. 2019 Oct 1;5(10):1403-1405
Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance.
Martins F, Sofiya L, Sykiotis GP, Lamine F, Maillard M, Fraga M, Shabafrouz K, Ribi C, Cairoli A, Guex-Crosier Y, Kuntzer T, Michielin O, Peters S, Coukos G, Spertini F, Thompson JA, Obeid M
Nat Rev Clin Oncol. 2019 Sep;16(9):563-580
Preanalytic Variables and Tissue Stewardship for Reliable Next-Generation Sequencing (NGS) Clinical Analysis.
Ascierto PA, Bifulco C, Palmieri G, Peters S, Sidiropoulos N
J Mol Diagn. 2019 Sep;21(5):756-767
(18)F-FDG PET metabolic-to-morphological volume ratio predicts PD-L1 tumour expression and response to PD-1 blockade in non-small-cell lung cancer.
Jreige M, Letovanec I, Chaba K, Renaud S, Rusakiewicz S, Cristina V, Peters S, Krueger T, de Leval L, Kandalaft LE, Nicod-Lalonde M, Romero P, Prior JO, Coukos G, Schaefer N
Eur J Nucl Med Mol Imaging. 2019 Aug;46(9):1859-1868
Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis.
Dafni U, Tsourti Z, Vervita K, Peters S
Lung Cancer. 2019 Aug;134:127-140
Implementation of the Symptom Navi © Programme for cancer patients in the Swiss outpatient setting: a study protocol for a cluster randomised pilot study (Symptom Navi© Pilot Study).
Bana M, Ribi K, Kropf-Staub S, Zürcher-Florin S, Näf E, Manser T, Bütikofer L, Rintelen F, Peters S, Eicher M
BMJ Open. 2019 Jul 9;9(7):e027942
Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX Study.
Camidge DR, Dziadziuszko R, Peters S, Mok T, Noe J, Nowicka M, Gadgeel SM, Cheema P, Pavlakis N, de Marinis F, Cho BC, Zhang L, Moro-Sibilot D, Liu T, Bordogna W, Balas B, Müller B, Shaw AT
J Thorac Oncol. 2019 Jul;14(7):1233-1243
Afatinib in NSCLC With HER2 Mutations: Results of the Prospective, Open-Label Phase II NICHE Trial of European Thoracic Oncology Platform (ETOP).
Dziadziuszko R, Smit EF, Dafni U, Wolf J, Wasąg B, Biernat W, Finn SP, Kammler R, Tsourti Z, Rabaglio M, Ruepp B, Roschitzki-Voser H, Stahel RA, Felip E, Peters S
J Thorac Oncol. 2019 Jun;14(6):1086-1094
[The new management options for lung cancer in the immunotherapy era].
Meganem H, Socianu RM, Bouchaab H, Mederos N, Nguyen-Ngoc T, Peters S, Dolcan A
Rev Med Suisse. 2019 May 15;15(651):1032-1037
De sérieuses préoccupations qui ne cachent pas nos espoirs.
Aapro M, Peters S, Dietrich PY
Rev Med Suisse. 2019 May 15;15(651):999-1000
Immunotherapy for the First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer.
Martinez P, Peters S, Stammers T, Soria JC
Clin Cancer Res. 2019 May 1;25(9):2691-2698
A retrospective cohort study of PD-L1 prevalence, molecular associations and clinical outcomes in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape Project.
Kerr KM, Thunnissen E, Dafni U, Finn SP, Bubendorf L, Soltermann A, Verbeken E, Biernat W, Warth A, Marchetti A, Speel EM, Pokharel S, Quinn AM, Monkhorst K, Navarro A, Madsen LB, Radonic T, Wilson J, De Luca G, Gray SG, Cheney R, Savic S, Martorell M, Mu
Lung Cancer. 2019 May;131:95-103
Preoperative chemotherapy and radiotherapy concomitant to cetuximab in resectable stage IIIB NSCLC: a multicentre phase 2 trial (SAKK 16/08).
Curioni-Fontecedro A, Perentes JY, Gelpke H, Xyrafas A, Bouchaab H, Mach N, Matzinger O, Stojcheva N, Frueh M, Weder W, Cathomas R, Gargiulo P, Bubendorf L, Pless M, Betticher D, Peters S, Swiss Group of Clinical Cancer Research (SAKK)
Br J Cancer. 2019 May;120(10):968-974
Afatinib in patients with metastatic or recurrent HER2-mutant lung cancers: a retrospective international multicentre study.
Lai WV, Lebas L, Barnes TA, Milia J, Ni A, Gautschi O, Peters S, Ferrara R, Plodkowski AJ, Kavanagh J, Sabari JK, Clarke SJ, Pavlakis N, Drilon A, Rudin CM, Arcila ME, Leighl NB, Shepherd FA, Kris MG, Mazières J, Li BT
Eur J Cancer. 2019 Mar;109:28-35
Brain metastases.
Achrol AS, Rennert RC, Anders C, Soffietti R, Ahluwalia MS, Nayak L, Peters S, Arvold ND, Harsh GR, Steeg PS, Chang SD
Nat Rev Dis Primers. 2019 Jan 17;5(1):5
[Oncology, what's new in 2018].
Latifyan S, Kakourou A, Ozdemir B, Zaman K, Vernadou A, Berthold D, Abdelhamid K, Bouchaab H, Peters S, Montemurro M, Aedo V, Michielin O, Zimmermann S, Stravodimou A
Rev Med Suisse. 2019 Jan 9;15(N° 632-633):78-81
Trastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2-Overexpressing Metastatic Non-Small Cell Lung Cancer: Efficacy, Safety, and Biomarkers.
Peters S, Stahel R, Bubendorf L, Bonomi P, Villegas A, Kowalski DM, Baik CS, Isla D, Carpeno JC, Garrido P, Rittmeyer A, Tiseo M, Meyenberg C, de Haas S, Lam LH, Lu MW, Stinchcombe TE
Clin Cancer Res. 2019 Jan 1;25(1):64-72
Multimodal Treatment in Operable Stage III NSCLC: A Pooled Analysis on Long-Term Results of Three SAKK trials (SAKK 16/96, 16/00, and 16/01).
Früh M, Betticher DC, Stupp R, Xyrafas A, Peters S, Ris HB, Mirimanoff RO, Ochsenbein AF, Schmid R, Matzinger O, Stahel RA, Weder W, Guckenberger M, Rothschild SI, Lardinois D, Mach N, Mark M, Gautschi O, Thierstein S, Biaggi Rudolf C, Pless M, Swiss Grou
J Thorac Oncol. 2019 Jan;14(1):115-123
Characterisation of rare haematological immune-related toxicities.
Haanen JB, Peters S
Lancet Haematol. 2019 Jan;6(1):e10-e11
New therapeutic perspectives to manage refractory immune checkpoint-related toxicities.
Martins F, Sykiotis GP, Maillard M, Fraga M, Ribi C, Kuntzer T, Michielin O, Peters S, Coukos G, Spertini F, Thompson JA, Obeid M
Lancet Oncol. 2019 Jan;20(1):e54-e64
Activity of Afatinib in Heavily Pretreated Patients With ERBB2 Mutation-Positive Advanced NSCLC: Findings From a Global Named Patient Use Program.
Peters S, Curioni-Fontecedro A, Nechushtan H, Shih JY, Liao WY, Gautschi O, Spataro V, Unk M, Yang JC, Lorence RM, Carrière P, Cseh A, Chang GC
J Thorac Oncol. 2018 Dec;13(12):1897-1905
Computer-Based Intensity Measurement Assists Pathologists in Scoring Phosphatase and Tensin Homolog Immunohistochemistry - Clinical Associations in NSCLC Patients of the European Thoracic Oncology Platform Lungscape Cohort.
Rulle U, Tsourti Z, Casanova R, Deml KF, Verbeken E, Thunnissen E, Warth A, Cheney R, Sejda A, Speel EJ, Madsen LB, Nonaka D, Navarro A, Sansano I, Marchetti A, Finn SP, Monkhorst K, Kerr KM, Haberecker M, Wu C, Zygoura P, Kammler R, Geiger T, Gendreau S,
J Thorac Oncol. 2018 Dec;13(12):1851-1863
Phase Ib Trial With Birabresib, a Small-Molecule Inhibitor of Bromodomain and Extraterminal Proteins, in Patients With Selected Advanced Solid Tumors.
Lewin J, Soria JC, Stathis A, Delord JP, Peters S, Awada A, Aftimos PG, Bekradda M, Rezai K, Zeng Z, Hussain A, Perez S, Siu LL, Massard C
J Clin Oncol. 2018 Oct 20;36(30):3007-3014
Effect of national HIV testing recommendations and local interventions on HIV testing practices in a Swiss university hospital: a retrospective analysis between 2012 and 2015.
Lazzarino T, Martenet S, Mamin R, Du Pasquier RA, Peters S, Perreau M, Muller O, Hugli O, Cavassini M, Darling KEA
BMJ Open. 2018 Oct 3;8(10):e021203
Gender-related challenges facing oncologists: the results of the ESMO Women for Oncology Committee survey.
Banerjee S, Dafni U, Allen T, Arnold D, Curigliano G MD, Garralda E, Garassino MC, Haanen J, Hofstädter-Thalmann E, Robert C, Sessa C, Tsourti Z, Zygoura P, Peters S
ESMO Open. 2018;3(6):e000422
Report on the status of women occupying leadership roles in oncology.
Hofstädter-Thalmann E, Dafni U, Allen T, Arnold D, Banerjee S, Curigliano G MD, Garralda E, Garassino MC, Haanen J, Robert C, Sessa C, Tsourti Z, Zygoura P, Peters S
ESMO Open. 2018;3(6):e000423
Delineating the Role of PD-1/PD-L1 Blockade in Advanced SCLC.
Zimmermann S, Peters S
J Thorac Oncol. 2018 Sep;13(9):1242-1244
Acceptance of the Advanced Practice Nurse in Lung Cancer Role by Healthcare Professionals and Patients: A Qualitative Exploration.
Serena A, Dwyer AA, Peters S, Eicher M
J Nurs Scholarsh. 2018 Sep;50(5):540-548
Management of Resistance to First-Line Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor Therapy.
Peters S, Zimmermann S
Curr Treat Options Oncol. 2018 May 28;19(7):37
Immune Checkpoint Inhibitors in the Management of Lung Cancer.
Zimmermann S, Peters S, Owinokoko T, Gadgeel SM
Am Soc Clin Oncol Educ Book. 2018 May 23;38:682-695
De vrais espoirs et de sérieuses préoccupations.
Peters S, Dietrich PY, Aapro M
Rev Med Suisse. 2018 May 16;14(607):1011-1012
Genomic Features of Response to Combination Immunotherapy in Lung Cancer.
Früh M, Peters S
Cancer Cell. 2018 May 14;33(5):791-793
EML4-ALK Variant Affects ALK Resistance Mutations.
Früh M, Peters S
J Clin Oncol. 2018 Apr 20;36(12):1257-1259
RANKL Signaling Sustains Primary Tumor Growth in Genetically Engineered Mouse Models of Lung Adenocarcinoma.
Faget J, Contat C, Zangger N, Peters S, Meylan E
J Thorac Oncol. 2018 Mar;13(3):387-398
Evaluation of NGS and RT-PCR Methods for ALK Rearrangement in European NSCLC Patients: Results from the European Thoracic Oncology Platform Lungscape Project.
Letovanec I, Finn S, Zygoura P, Smyth P, Soltermann A, Bubendorf L, Speel EJ, Marchetti A, Nonaka D, Monkhorst K, Hager H, Martorell M, Sejda A, Cheney R, Hernandez-Losa J, Verbeken E, Weder W, Savic S, Di Lorito A, Navarro A, Felip E, Warth A, Baas P, Me
J Thorac Oncol. 2018 Mar;13(3):413-425
PD-1 blockade in advanced NSCLC: A focus on pembrolizumab.
Peters S, Kerr KM, Stahel R
Cancer Treat Rev. 2018 Jan;62:39-49
Immunotherapy for Unresectable Stage III Non-Small-Cell Lung Cancer.
Rizvi NA, Peters S
N Engl J Med. 2017 Nov 16;377(20):1986-1988
Prevalence and clinical association of MET gene overexpression and amplification in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape project.
Bubendorf L, Dafni U, Schöbel M, Finn SP, Tischler V, Sejda A, Marchetti A, Thunnissen E, Verbeken EK, Warth A, Sansano I, Cheney R, Speel EJM, Nonaka D, Monkhorst K, Hager H, Martorell M, Savic S, Kerr KM, Tan Q, Tsourti Z, Geiger TR, Kammler R, Schulze
Lung Cancer. 2017 Sep;111:143-149
Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.
Peters S, Camidge DR, Shaw AT, Gadgeel S, Ahn JS, Kim DW, Ou SI, Pérol M, Dziadziuszko R, Rosell R, Zeaiter A, Mitry E, Golding S, Balas B, Noe J, Morcos PN, Mok T, ALEX Trial Investigators
N Engl J Med. 2017 Aug 31;377(9):829-838
Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH).
Peters S, Gettinger S, Johnson ML, Jänne PA, Garassino MC, Christoph D, Toh CK, Rizvi NA, Chaft JE, Carcereny Costa E, Patel JD, Chow LQM, Koczywas M, Ho C, Früh M, van den Heuvel M, Rothenstein J, Reck M, Paz-Ares L, Shepherd FA, Kurata T, Li Z, Qiu J, K
J Clin Oncol. 2017 Aug 20;35(24):2781-2789
Feasibility of advanced practice nursing in lung cancer consultations during early treatment: A phase II study.
Serena A, Dwyer A, Peters S, Eicher M
Eur J Oncol Nurs. 2017 Aug;29:106-114
Scientific Advances in Thoracic Oncology 2016.
Soo RA, Stone ECA, Cummings KM, Jett JR, Field JK, Groen HJM, Mulshine JL, Yatabe Y, Bubendorf L, Dacic S, Rami-Porta R, Detterbeck FC, Lim E, Asamura H, Donington J, Wakelee HA, Wu YL, Higgins K, Senan S, Solomon B, Kim DW, Johnson M, Yang JCH, Sequist L
J Thorac Oncol. 2017 Aug;12(8):1183-1209
Patient and doctor perspectives on HIV screening in the emergency department: A prospective cross-sectional study.
De Rossi N, Dattner N, Cavassini M, Peters S, Hugli O, Darling KEA
PLoS One. 2017;12(7):e0180389
First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer.
Carbone DP, Reck M, Paz-Ares L, Creelan B, Horn L, Steins M, Felip E, van den Heuvel MM, Ciuleanu TE, Badin F, Ready N, Hiltermann TJN, Nair S, Juergens R, Peters S, Minenza E, Wrangle JM, Rodriguez-Abreu D, Borghaei H, Blumenschein GR Jr, Villaruz LC, Ha
N Engl J Med. 2017 Jun 22;376(25):2415-2426
L’accès à l’innovation.
Aapro M, Dietrich PY, Peters S
Rev Med Suisse. 2017 May 17;13(563):1027
Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial.
Rosell R, Dafni U, Felip E, Curioni-Fontecedro A, Gautschi O, Peters S, Massutí B, Palmero R, Aix SP, Carcereny E, Früh M, Pless M, Popat S, Kotsakis A, Cuffe S, Bidoli P, Favaretto A, Froesch P, Reguart N, Puente J, Coate L, Barlesi F, Rauch D, Thomas M,
Lancet Respir Med. 2017 May;5(5):435-444
Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Maintenance Therapy for Patients With Advanced Nonsquamous Non-Small-cell Lung Cancer: Update From the Swiss Group for Clinical Cancer Research (SAKK) 19/09 Trial.
Gautschi O, Rothschild SI, Li Q, Matter-Walstra K, Zippelius A, Betticher DC, Früh M, Stahel RA, Cathomas R, Rauch D, Pless M, Peters S, Froesch P, Zander T, Schneider M, Biaggi C, Mach N, Ochsenbein AF, Swiss Group for Clinical Cancer Research
Clin Lung Cancer. 2017 May;18(3):303-309
Randomized Phase III Trial of Erlotinib versus Docetaxel in Patients with Advanced Squamous Cell Non-Small Cell Lung Cancer Failing First-Line Platinum-Based Doublet Chemotherapy Stratified by VeriStrat Good versus VeriStrat Poor. The European Thoracic On
Peters S, Stahel RA, Dafni U, Ponce Aix S, Massutí B, Gautschi O, Coate L, López Martín A, van Heemst R, Berghmans T, Meldgaard P, Cobo Dols M, Garde Noguera J, Curioni-Fontecedro A, Rauch D, Mark MT, Cuffe S, Biesma B, van Henten AMJ, Juan Vidal Ó, Palme
J Thorac Oncol. 2017 Apr;12(4):752-762
The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC.
Manegold C, Dingemans AC, Gray JE, Nakagawa K, Nicolson M, Peters S, Reck M, Wu YL, Brustugun OT, Crinò L, Felip E, Fennell D, Garrido P, Huber RM, Marabelle A, Moniuszko M, Mornex F, Novello S, Papotti M, Pérol M, Smit EF, Syrigos K, van Meerbeeck JP, va
J Thorac Oncol. 2017 Feb;12(2):194-207
Biosimilars: a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers.
Tabernero J, Vyas M, Giuliani R, Arnold D, Cardoso F, Casali PG, Cervantes A, Eggermont AMM, Eniu A, Jassem J, Pentheroudakis G, Peters S, Rauh S, Zielinski CC, Stahel RA, Voest E, Douillard JY, McGregor K, Ciardiello F
ESMO Open. 2016;1(6):e000142
Novel active agents in patients with advanced NSCLC without driver mutations who have progressed after first-line chemotherapy.
Manegold C, Adjei A, Bussolino F, Cappuzzo F, Crino L, Dziadziuszko R, Ettinger D, Fennell D, Kerr K, Le Chevalier T, Leighl N, Papotti M, Paz-Ares L, Pérol M, Peters S, Pirker R, Quoix E, Reck M, Smit E, Vokes E, van Zandwijk N, Zhou C
ESMO Open. 2016;1(6):e000118
Career opportunities and benefits for young oncologists in the European Society for Medical Oncology (ESMO).
Morgan G, Lambertini M, Kourie HR, Amaral T, Argiles G, Banerjee S, Cardone C, Corral J, De Mattos-Arruda L, Öztürk A, Petrova M, Poulsen L, Strijbos M, Tyulyandina A, Vidra R, Califano R, de Azambuja E, Garrido Lopez P, Guarneri V, Reck M, Moiseyenko V,
ESMO Open. 2016;1(6):e000107
Investigating Barriers in HIV-Testing Oncology Patients: The IBITOP Study, Phase I.
Merz L, Zimmermann S, Peters S, Cavassini M, Darling KE
Oncologist. 2016 Oct;21(10):1176-1182
Scientific Advances in Lung Cancer 2015.
Tsao AS, Scagliotti GV, Bunn PA Jr, Carbone DP, Warren GW, Bai C, de Koning HJ, Yousaf-Khan AU, McWilliams A, Tsao MS, Adusumilli PS, Rami-Porta R, Asamura H, Van Schil PE, Darling GE, Ramalingam SS, Gomez DR, Rosenzweig KE, Zimmermann S, Peters S, Ignati
J Thorac Oncol. 2016 May;11(5):613-638
The impact of brain metastasis on quality of life, resource utilization and survival in patients with non-small-cell lung cancer.
Peters S, Bexelius C, Munk V, Leighl N
Cancer Treat Rev. 2016 Apr;45:139-62
Emerging Options After Progression During Crizotinib Therapy.
Peters S
J Clin Oncol. 2016 Mar 1;34(7):643-5
Apnea-like suppression of respiratory motion: First evaluation in radiotherapy.
Péguret N, Ozsahin M, Zeverino M, Belmondo B, Durham AD, Lovis A, Simons J, Long O, Duclos F, Prior J, Denys A, Beigelman C, Sozzi WJ, Grant K, Gautier-Dechaud V, Peters S, Vienne M, Moeckli R, Bourhis J
Radiother Oncol. 2016 Feb;118(2):220-6
Survival and Local Recurrence After Video-Assisted Thoracoscopic Lung Metastasectomy.
Abdelnour-Berchtold E, Perentes JY, Ris HB, Beigelman C, Lovis A, Peters S, Krueger T, Gonzalez M
World J Surg. 2016 Feb;40(2):373-9
Seeking New Approaches to Patients With Small Cell Lung Cancer.
Pietanza MC, Zimmerman S, Peters S, Curran WJ Jr
Am Soc Clin Oncol Educ Book. 2016;35:e477-82
Patients' understanding of blood tests and attitudes to HIV screening in the emergency department of a Swiss teaching hospital: a cross-sectional observational study.
Favre-Bulle T, Baudat D, Darling KE, Mamin R, Peters S, Cavassini M, Hugli O
Swiss Med Wkly. 2015;145:w14206
Treatment of pleural malignancies by photo-induction combined to systemic chemotherapy: Proof of concept on rodent lung tumors and feasibility study on porcine chest cavities.
Wang X, Gronchi F, Bensimon M, Mercier T, Decosterd LA, Wagnières G, Debefve E, Ris HB, Letovanec I, Peters S, Perentes JY
Lasers Surg Med. 2015 Dec;47(10):807-16
Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial.
Stahel RA, Riesterer O, Xyrafas A, Opitz I, Beyeler M, Ochsenbein A, Früh M, Cathomas R, Nackaerts K, Peters S, Mamot C, Zippelius A, Mordasini C, Caspar CB, Eckhardt K, Schmid RA, Aebersold DM, Gautschi O, Nagel W, Töpfer M, Krayenbuehl J, Ribi K, Cierni
Lancet Oncol. 2015 Dec;16(16):1651-8
[Is prescription of a therapy costing 150,000 CHF reasonable?].
Peters S, von Moos R, Thurlimann B
Rev Med Suisse. 2015 Oct 21;11(491):1967-72
BRAF Alterations as Therapeutic Targets in Non-Small-Cell Lung Cancer.
Nguyen-Ngoc T, Bouchaab H, Adjei AA, Peters S
J Thorac Oncol. 2015 Oct;10(10):1396-403
Targeted Therapy for Patients with BRAF-Mutant Lung Cancer: Results from the European EURAF Cohort.
Gautschi O, Milia J, Cabarrou B, Bluthgen MV, Besse B, Smit EF, Wolf J, Peters S, Früh M, Koeberle D, Oulkhouir Y, Schuler M, Curioni-Fontecedro A, Huret B, Kerjouan M, Michels S, Pall G, Rothschild S, Schmid-Bindert G, Scheffler M, Veillon R, Wannesson L
J Thorac Oncol. 2015 Oct;10(10):1451-7
Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial.
Pless M, Stupp R, Ris HB, Stahel RA, Weder W, Thierstein S, Gerard MA, Xyrafas A, Früh M, Cathomas R, Zippelius A, Roth A, Bijelovic M, Ochsenbein A, Meier UR, Mamot C, Rauch D, Gautschi O, Betticher DC, Mirimanoff RO, Peters S, SAKK Lung Cancer Project G
Lancet. 2015 Sep 12;386(9998):1049-56
Bevacizumab, Pemetrexed, and Cisplatin, or Bevacizumab and Erlotinib for Patients With Advanced Non-Small-Cell Lung Cancer Stratified by Epidermal Growth Factor Receptor Mutation: Phase II Trial SAKK19/09.
Gautschi O, Mach N, Rothschild SI, Li Q, Stahel RA, Zippelius A, Cathomas R, Früh M, Betticher DC, Peters S, Rauch D, Feilchenfeldt J, Bubendorf L, Savic S, Jaggi R, Leibundgut EO, Largiadèr C, Brutsche M, Pilop C, Stalder L, Pless M, Ochsenbein AF, Swiss
Clin Lung Cancer. 2015 Sep;16(5):358-65
Present standards and future perspectives in the treatment of metastatic non-small cell lung cancer.
Zimmermann S, Peters S
Cancer Metastasis Rev. 2015 Jun;34(2):173-82
Lung cancer. How much platinum-based chemotherapy is enough in NSCLC?
Peters S, Adjei AA
Nat Rev Clin Oncol. 2015 Jan;12(1):8-10
Investigating barriers in HIV-testing oncology patients. The IBITOP study: phase I.
Merz L, Peters S, Zimmermann S, Cavassini M, Darling K
J Int AIDS Soc. 2014;17(4 Suppl 3):19622
Pan-HER inhibition in EGFR wild-type non-small-cell lung cancer.
Peters S, Smit E
Lancet Oncol. 2014 Nov;15(12):1289-90
Lungscape: resected non-small-cell lung cancer outcome by clinical and pathological parameters.
Peters S, Weder W, Dafni U, Kerr KM, Bubendorf L, Meldgaard P, O'Byrne KJ, Wrona A, Vansteenkiste J, Felip E, Marchetti A, Savic S, Lu S, Smit E, Dingemans AM, Blackhall FH, Baas P, Camps C, Rosell R, Stahel RA, ETOP Lungscape Investigators
J Thorac Oncol. 2014 Nov;9(11):1675-84
Dramatic response of vemurafenib-induced cutaneous lesions upon switch to dual BRAF/MEK inhibition in a metastatic melanoma patient.
Peters S, Bouchaab H, Zimmerman S, Bucher M, Gaide O, Letovanec I, Homicsko K, Michielin O
Melanoma Res. 2014 Oct;24(5):496-500
Prevalence and clinical outcomes for patients with ALK-positive resected stage I to III adenocarcinoma: results from the European Thoracic Oncology Platform Lungscape Project.
Blackhall FH, Peters S, Bubendorf L, Dafni U, Kerr KM, Hager H, Soltermann A, O'Byrne KJ, Dooms C, Sejda A, Hernández-Losa J, Marchetti A, Savic S, Tan Q, Thunnissen E, Speel EJ, Cheney R, Nonaka D, de Jong J, Martorell M, Letovanec I, Rosell R, Stahel RA
J Clin Oncol. 2014 Sep 1;32(25):2780-7
Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: comparative pharmacokinetics and drug-drug interactions.
Peters S, Zimmermann S, Adjei AA
Cancer Treat Rev. 2014 Sep;40(8):917-26
2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease.
Besse B, Adjei A, Baas P, Meldgaard P, Nicolson M, Paz-Ares L, Reck M, Smit EF, Syrigos K, Stahel R, Felip E, Peters S, Panel Members., ESMO.
Ann Oncol. 2014 Aug;25(8):1475-84
Comprehensive molecular profiling of lung adenocarcinoma.
Cancer Genome Atlas Research Network.
Nature. 2014 Jul 31;511(7511):543-50
Indications and limitations of chemotherapy and targeted agents in non-small cell lung cancer brain metastases.
Zimmermann S, Dziadziuszko R, Peters S
Cancer Treat Rev. 2014 Jul;40(6):716-22
Low-Dose Vascular Photodynamic Therapy Decreases Tumor Interstitial Fluid Pressure, which Promotes Liposomal Doxorubicin Distribution in a Murine Sarcoma Metastasis Model.
Perentes JY, Wang Y, Wang X, Abdelnour E, Gonzalez M, Decosterd L, Wagnieres G, van den Bergh H, Peters S, Ris HB, Krueger T
Transl Oncol. 2014 May 13;7(3):393-9
Targeted therapy in NSCLC driven by HER2 insertions.
Peters S, Zimmermann S
Transl Lung Cancer Res. 2014 Apr;3(2):84-8
Cerebral nocardiosis mimicking multiple brain metastases in a patient with locally advanced non-small-cell lung cancer.
Voide C, Zimmermann S, Adjei AA, Betticher DC, Meuli R, Prod'hom G, Giulieri S, Peters S
J Thorac Oncol. 2014 Mar;9(3):e24-6
ALK inhibitors in the treatment of advanced NSCLC.
Gridelli C, Peters S, Sgambato A, Casaluce F, Adjei AA, Ciardiello F
Cancer Treat Rev. 2014 Mar;40(2):300-6
Strategies for improving outcomes in NSCLC: a look to the future.
Stahel R, Peters S, Baas P, Brambilla E, Cappuzzo F, De Ruysscher D, Eberhardt WE, Felip E, Fennell D, Marchetti A, Paz-Ares L, Adjei AA
Lung Cancer. 2013 Dec;82(3):375-82
Lung adenocarcinoma with BRAF G469L mutation refractory to vemurafenib.
Gautschi O, Peters S, Zoete V, Aebersold-Keller F, Strobel K, Schwizer B, Hirschmann A, Michielin O, Diebold J
Lung Cancer. 2013 Nov;82(2):365-7
Identification of multiple mechanisms of resistance to vemurafenib in a patient with BRAFV600E-mutated cutaneous melanoma successfully rechallenged after progression.
Romano E, Pradervand S, Paillusson A, Weber J, Harshman K, Muehlethaler K, Speiser D, Peters S, Rimoldi D, Michielin O
Clin Cancer Res. 2013 Oct 15;19(20):5749-57
Practical tips and tricks with recently approved molecular targeted agents in non-small-cell lung cancer.
Zimmermann S, Peters S
EJC Suppl. 2013 Sep;11(2):307-9
Treatment and detection of ALK-rearranged NSCLC.
Peters S, Taron M, Bubendorf L, Blackhall F, Stahel R
Lung Cancer. 2013 Aug;81(2):145-54
Dramatic response induced by vemurafenib in a BRAF V600E-mutated lung adenocarcinoma.
Peters S, Michielin O, Zimmermann S
J Clin Oncol. 2013 Jul 10;31(20):e341-4
Impact of induction therapy on airway complications after sleeve lobectomy for lung cancer.
Gonzalez M, Litzistorf Y, Krueger T, Popeskou SG, Matzinger O, Ris HB, Gronchi F, Lovis A, Peters S
Ann Thorac Surg. 2013 Jul;96(1):247-52
Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives.
Mazières J, Peters S, Lepage B, Cortot AB, Barlesi F, Beau-Faller M, Besse B, Blons H, Mansuet-Lupo A, Urban T, Moro-Sibilot D, Dansin E, Chouaid C, Wislez M, Diebold J, Felip E, Rouquette I, Milia JD, Gautschi O
J Clin Oncol. 2013 Jun 1;31(16):1997-2003
Testing for anaplastic lymphoma kinase rearrangement to target crizotinib therapy: oncology, pathology and health economic perspectives.
Lee JA, Bubendorf L, Stahel R, Peters S
Expert Rev Anticancer Ther. 2013 May;13(5):625-36
A dramatic lung cancer course in a patient with a rare EGFR germline mutation exon 21 V843I: Is EGFR TKI resistance predictable?
Demierre N, Zoete V, Michielin O, Stauffer E, Zimmermann DR, Betticher DC, Peters S
Lung Cancer. 2013 Apr;80(1):81-4
Targeting receptor activator of nuclear factor-kappa B as a new therapy for bone metastasis in non-small cell lung cancer.
Peters S, Meylan E
Curr Opin Oncol. 2013 Mar;25(2):137-44
VeriStrat® has a prognostic value for patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab in the first line: pooled analysis of SAKK19/05 and NTR528.
Gautschi O, Dingemans AM, Crowe S, Peters S, Roder H, Grigorieva J, Roder J, Zappa F, Pless M, Brutsche M, Baty F, Bubendorf L, Hsu Schmitz SF, Na KJ, Carbone D, Stahel R, Smit E
Lung Cancer. 2013 Jan;79(1):59-64
Impact of lung function changes after induction radiochemotherapy on resected T4 non-small cell lung cancer outcome.
Perentes J, Bopp S, Krueger T, Gonzalez M, Jayet PY, Lovis A, Matzinger O, Ruffieux C, Ris HB, Letovanec I, Peters S
Ann Thorac Surg. 2012 Dec;94(6):1815-22
Therapeutic advances in non-small cell lung cancer.
Vallières E, Peters S, Van Houtte P, Dalal P, Lim E
Thorax. 2012 Dec;67(12):1097-101
Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Peters S, Adjei AA, Gridelli C, Reck M, Kerr K, Felip E, ESMO Guidelines Working Group.
Ann Oncol. 2012 Oct;23 Suppl 7:vii56-64
Pulmonary sarcoid-like granulomatosis induced by ipilimumab.
Berthod G, Lazor R, Letovanec I, Romano E, Noirez L, Mazza Stalder J, Speiser DE, Peters S, Michielin O
J Clin Oncol. 2012 Jun 10;30(17):e156-9
MET: a promising anticancer therapeutic target.
Peters S, Adjei AA
Nat Rev Clin Oncol. 2012 May 8;9(6):314-26
Photodynamic induced uptake of liposomal doxorubicin to rat lung tumors parallels tumor vascular density.
Wang Y, Gonzalez M, Cheng C, Haouala A, Krueger T, Peters S, Decosterd LA, van den Bergh H, Perentes JY, Ris HB, Letovanec I, Debefve E
Lasers Surg Med. 2012 Apr;44(4):318-24
Outcome, quality of life and cognitive function of patients with brain metastases from non-small cell lung cancer treated with whole brain radiotherapy combined with gefitinib or temozolomide. A randomised phase II trial of the Swiss Group for Clinical Ca
Pesce GA, Klingbiel D, Ribi K, Zouhair A, von Moos R, Schlaeppi M, Caspar CB, Fischer N, Anchisi S, Peters S, Cathomas R, Bernhard J, Kotrubczik NM, D'Addario G, Pilop C, Weber DC, Bodis S, Pless M, Mayer M, Stupp R
Eur J Cancer. 2012 Feb;48(3):377-84
HIV testing practices by clinical service before and after revised testing guidelines in a Swiss University Hospital.
Darling KE, Hugli O, Mamin R, Cellerai C, Martenet S, Berney A, Peters S, Du Pasquier RA, Bodenmann P, Cavassini M
PLoS One. 2012;7(6):e39299
Extrapleural pneumonectomy with venous confluence resection for stage IVA thymic tumors.
Gonzalez M, Krueger T, Perentes JY, Matzinger O, Peters S, Ris HB
Ann Thorac Surg. 2011 Mar;91(3):941-3
Trimodality therapy for locally advanced non-small-cell lung cancer: a curative approach.
Stupp R, Betticher D, Ris HB, Peters S, Pless M
J Clin Oncol. 2011 Feb 10;29(5):e118-9; author reply e120
Photodynamic therapy selectively enhances liposomal doxorubicin uptake in sarcoma tumors to rodent lungs.
Cheng C, Debefve E, Haouala A, Andrejevic-Blant S, Krueger T, Ballini JP, Peters S, Decosterd L, van den Bergh H, Wagnieres G, Perentes JY, Ris HB
Lasers Surg Med. 2010 Jul;42(5):391-9
Solitary choriocarcinoma in the lung.
Berthod G, Bouzourene H, Pachinger C, Peters S
J Thorac Oncol. 2010 Apr;5(4):574-5
Thalidomide in small cell lung cancer: wrong drug or wrong disease?
Rüegg C, Peters S
J Natl Cancer Inst. 2009 Aug 5;101(15):1034-5
Neoadjuvant chemotherapy and radiotherapy followed by surgery in selected patients with stage IIIB non-small-cell lung cancer: a multicentre phase II trial.
Stupp R, Mayer M, Kann R, Weder W, Zouhair A, Betticher DC, Roth AD, Stahel RA, Majno SB, Peters S, Jost L, Furrer M, Thierstein S, Schmid RA, Hsu-Schmitz SF, Mirimanoff RO, Ris HB, Pless M
Lancet Oncol. 2009 Aug;10(8):785-93
Education et formation
Professeure ordinaire (UNIL): 2019
Professeure associée (UNIL): 2016
European Society for Medical Oncology (ESMO) examen en oncologie: 2006/12
Certficat de bonnes pratiques pour investigateurs et coordinateurs d'études-Swissmedic niveau 1-3: 2006/10/12
Société Suisse d'Oncologie Médicale, examen oral: 2006
PhD: 2002
Doctorat en médecine: 1998
Institutions de formation & expériences précédentes
Université de Lausanne
Università di Bari
Langues parlées
Français, Allemand, Italien, Anglais
Rue du Bugnon 46
CH-1011 Lausanne, Vaud, Suisse
+41 21 314 0155
Rue du Bugnon 46
CH-1011 Lausanne, Vaud, Suisse
+41 21 314 0155